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Summary 
Introduction 
Health Problem 
The scope of this assessment includes benign prostatic hyperplasia (BPH) 
causing moderate-to-severe lower urinary tract symptoms (LUTS). Benign 
enlargement of the prostate gland, bladder outlet obstruction, and LUTS are 
independent factors, in any combination referred to as LUTS suggestive of 
BPH. The symptoms of BPH are classified as voiding (e.g. hesitancy, intermit-
tency, dysuria), storage (e.g. frequency, nocturia, urgency) or post-micturition 
symptoms (e.g. incomplete voiding, dribbling). Approximately 2.5 per cent 
of men with untreated symptomatic BPH will develop acute urinary reten-
tion, and another six per cent will require invasive therapy within five years. 
The severity of LUTS is measured using the International Prostate Symptom 
Scores (IPSS) questionnaire, whereby a score of 1-7 indicates mild symptoms, 
8-10 moderate, and 20-35 severe. The global prevalence of histological BPH 
is estimated to be 42 per cent of men aged between 51 and 60, and 82 per cent 
of men aged between 71 and 80. However, not all of these men will be symp-
tomatic or require treatment. A representative survey of Austrian men esti-
mated the prevalence of moderate-to-severe LUTS to be 9.1 per cent of men 
between the ages of 15 and 89, noting that BPH is not the only cause of LUTS. 
 
Description of Technology 
Prostate artery embolisation (PAE) is a minimally invasive alternative to sur-
gical resection, which aims to shrink the prostate gland rather than remove 
it. In PAE, an interventional radiologist inserts a catheter into the femoral 
artery at the top of the leg, and guides the catheter to the prostate arteries. A 
solution of microscopic particles is injected through the catheter, which me-
chanically block the prostate arteries and partially reduce the blood supply. 
The reduction in blood supply induces ischaemic necrosis, causing the gland 
to soften and shrink in size over time.  
There are at least four different types of embolisation agents that can be used 
in PAE, which vary in size and material, but all of which operate under the 
same biomechanical principles. 
 
Methods 
In patients with BPH and moderate-to-severe LUTS, is PAE safer concerning 
adverse events, and as effective concerning changes in IPSS, International In-
dex of Erectile Function (IIEF) score, and quality of life scores, compared to 
surgical resection? 
The research question was investigated through a systematic review of the 
current literature on PAE. Four databases (Medline, Embase, Cochrane Li-
brary, CRD-Database) were searched; two authors independently conducted 
the study selection, data extraction, and quality appraisal.  
 
benign prostatic 
hyperplasia (BPH) 
causes  
moderate-to-severe 
lower urinary tract 
symptoms (LUTS):  
problems with urination 
severity of LUTS: 
measured with IPSS 
 
prevalence:  
42% men 51-60 y 
82% men 71-80 y  
not all symptomatic 
prostate artery 
embolisation (PAE): 
minimally invasive 
therapy 
microscopic particles 
injected to block the 
prostate arteries 
four different types  
of embolisation agents  
research question: 
efficacy and safety  
of PAE 
systematic search  
in 4 databases,  
2 authors: study 
selection, extraction, 
quality appraisal 
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Results 
Effectiveness outcomes were addressed by randomised controlled trials (RCTs) 
and non-randomised studies comparing PAE to transurethral resection of the 
prostate (TURP) or open prostatectomy. For safety outcomes, further five 
studies (e.g. single arm trials with at least 150 participants) were included. 
Two RCTs comparing PAE to TURP (n = 144), and one matched-pairs study 
comparing PAE to open prostatectomy (n = 160), were identified for effective-
ness outcomes. In addition to these studies, one additional RCT comparing 
PAE particle sizes, two non-randomised studies comparing different popula-
tions treated with PAE, and two single-arm studies of PAE were included for 
safety outcomes. The additional studies included a total of 1,168 patients. 
All studies with one exception included patients with more severe symptoms 
(IPSS ≥ 8). The mean age of all included patients ranged between 63 to 73 
years (for effectiveness analysis) and 63 to 83 years (for safety analysis). 
Clinical effectiveness 
The overall strength of evidence for the effectiveness of PAE compared to 
TURP was low. The included RCTs demonstrated conflicting evidence in re-
lation to improvements in IPSS and HRQoL at 12 months. The larger trial 
(n = 114) reported no significant differences in IPSS and HRQoL at 12 or 24 
months between PAE and TURP, whereas the smaller trial (n = 30) favoured 
TURP for both outcomes at 12 months. Disease progression was a rare out-
come, and as such meaningful comparisons between PAE and TURP cannot 
be drawn for this outcome. There was no long-term data beyond 24 months. 
The overall strength of evidence for the effectiveness of PAE compared to 
open prostatectomy was low. The matched-pairs trial reported open prostatec-
tomy was associated with a significantly greater improvement in mean IPSS 
(-19.04 vs. -13.58, P < 0.01) at 12 months compared to PAE. Disease pro-
gression was a rare outcome, and as such meaningful comparisons between 
PAE and open prostatectomy could not be formed for this outcome. There 
was no long-term data beyond 12 months. 
Safety 
The overall strength of evidence for the safety of PAE compared to TURP and 
open prostatectomy was low or moderate. There were no reported cases of peri-
operative mortality in any of the included studies. One RCT reported PAE 
to be associated with significantly more adverse events compared to TURP, 
while the matched-pairs trial found significantly fewer adverse events for PAE 
compared to open prostatectomy.  
The overall strength of evidence for the safety of PAE from non-randomised 
and single-arm studies was low or very low. Serious adverse events were rare, 
and included one case of bladder wall ischemia, and eight technical or clini-
cal failures across the entire safety population (n = 1,472). The most common-
ly reported adverse events associated with PAE were minor, including ure-
thral burning (range 10.2% to 100.0%), acute urinary retention (range 8.6% 
to 30.8%), blood in the urine (range 0.0% to 13.3%), blood in the semen (range 
1.25% to 11.2%), and urinary tract infections (range 1.25% to 4.8%). 
available evidence: 
efficacy (n = 304 pts): 
comparative studies 
with TURP or open 
prostatectomy:  
2 RCTs,  
1 matched-pairs study 
 
safety  
(n = 304 + 1,168 pts):  
observational studies 
and RCTs comparing 
different agents or 
patient groups 
 
pts characteristics 
PAE vs TURP 
low strength of 
evidence:  
conflicting evidence in 
improvements in IPSS 
and HRQoL at 12 months 
no long-term data 
beyond 24 months 
PAE vs OP 
low strength of 
evidence: 
significant better 
improvement in IPSS 
and IIEF at 12 months 
with OP 
PAE vs TURP vs OP 
moderate to low 
strength of evidence  
 
no perioperative 
mortality 
SAE: rare 
 
AE conflicting evidence 
on minor AE 
urethral burning,  
acute urinary retention, 
blood in the urine etc. 
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Upcoming evidence 
There are five ongoing RCTs of PAE compared to TURP in patients with 
moderate-to-severe LUTS, which are currently scheduled for completion be-
fore February 2021. In addition, there is one ongoing RCT of PAE compared 
to medical therapy, scheduled for completion in February 2021, and one RCT 
of PAE compared to sham procedure, scheduled for completion in September 
2017. In addition to the ongoing RCTs, there is one substantive non-random-
ised registry trial comparing PAE, TURP and open prostatectomy, which aims 
to enrol 300 patients, and is scheduled for completion in September 2017. 
Most of the ongoing trials are limited to 12-month follow-up, and as such 
will not fill the current evidence gap for the long-term safety and efficacy of 
PAE.  
 
Discussion and Conclusion 
The available RCTs reported conflicting results for the main effectiveness 
outcomes, and adverse events rates were reported variably across the includ-
ed studies. A consistent system for recording or rating the severity of adverse 
events was not present; however, severe adverse events were rare. The study 
populations were broadly generalizable in relation to symptoms, history, and 
demographics. Medium- to long-term follow-up data of safety and effective-
ness outcomes beyond 12-24 months are limited. It is currently unknown if 
placing embolisation particles in the prostate arteries may lead to long-term 
adverse events. Different embolisation agents were used in the included stud-
ies, including particles with a range of shapes, materials, and sizes. One RCT 
that compared outcomes of different sized particles found no significant dif-
ference in effectiveness or safety. It is unknown whether particle material or 
size have an impact on long-term outcomes.  
The current evidence is not sufficient to prove that PAE [in adult patients 
with moderate to severe LUTS] is as effective, but more safe than the com-
parator(s) TURP and open prostatectomy. New study results will potentially 
influence the effect estimate considerably. The re-evaluation is recommended 
in 2021. 
  
5 ongoing RCTs:  
PAE vs. TURP: 2021  
 
1 ongoing RCT: 
PAE vs. medical therapy 
 
Registry: PAE, TURP, OP 
conflicting results 
no consistent system  
of reporting 
(S)AE  
study populaton 
generalizable 
 
follow-up data: 
12-24 months 
 
different embolisation 
agents (size, shape, 
material) 
current evidence is  
not sufficient to prove 
effectiveness 
re-evaluation in 2021 
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Zusammenfassung 
Einführung 
Indikation und therapeutisches Ziel 
Bei der benignen Prostatahyperplasie (BPH) handelt es sich um eine gutarti-
ge Vergrößerung der männlichen Vorsteherdrüse (Prostata). Die BPH verur-
sacht eine Verengung der Harnröhre und damit mäßige-bis-schwere Sympto-
matiken der unteren Harnwege (lower urinary tract symptoms, LUTS), was mit 
Problemen beim Wasserlassen einhergeht. Die Symptome von LUTS sind ver-
zögertes Einsetzen der Blasenentleerung trotz starken Harndrangs, das Be-
dürfnis zu pressen, um die Blase zu entleeren (Pressmiktion), das Gefühl, die 
Blase werde nicht ganz leer (Restharnempfinden), ein schwacher Harnstrahl, 
nachtröpfelnder Urin, lange Dauer der Blasenentleerung und schon kurze 
Zeit nach dem Urinieren einsetzender erneuter Harndrang. Etwa 2,5 Prozent 
der Männer mit unbehandelten symptomatischen BPH entwickeln akute 
Harnretention (Harnverhaltung oder Ischurie), und weitere 6 Prozent benö-
tigen eine Therapie innerhalb von fünf Jahren.  
Der Schweregrad von LUTS wird mit dem Patientenfragebogen des Interna-
tional Prostate Symptom Scores (IPSS) gemessen, wobei eine Punktzahl von 1-7 
milde, 8-19 mäßige und 20-35 schwere Symptome, anzeigt.  
Die weltweite Prävalenz der BPH wird auf 42 Prozent der Männer im Alter 
zwischen 51 und 60 und bereits 82 Prozent der Männer im Alter zwischen 71 
und 80 geschätzt. Allerdings werden nicht alle diese Männer symptomatisch 
und/oder bedürfen eine Behandlung. Eine repräsentative Umfrage unter ös-
terreichischen Männern schätzte die Prävalenz von mäßiger bis schwerer 
LUTS auf 9,1 Prozent der Männer im Alter zwischen 15 und 89; allerdings 
ist festzuhalten, dass BPH nicht die einzige Ursache für LUTS ist.  
Da Störungen beim Wasserlassen bei älteren Männern relativ häufig sind und 
aufgrund der Symptomvielfalt der BPH, wird nur auf der Basis einer Stufen-
diagnostik eine Therapieempfehlung ausgesprochen. 
1. Anamnese einschließlich einer genauen Medikamentenanamnese  
2. IPSS (International Prostate Symptom Score) oder vergleichbare 
Symptomscores  
3. Körperliche Untersuchung mit digito-rektaler Untersuchung (DRU)  
4. Laboruntersuchungen: Serum-Kreatinin, Prostataspezifisches  
Antigen (PSA) (bei einem Lebensalter von über 50 Jahren), wenn sich 
daraus therapeutische Konsequenzen ergeben (dies allerdings derzeit 
fakultativ), Urinstatus und Urinsediment  
5. Uroflowmetrie 
6. Restharnbestimmung  
7. Uro-Sonographie (Nieren, Blase, Prostata  
[vorzugsweise Transurethraler Ultraschall (TRUS)]) 
Für die Behandlung der BPH steht eine Vielzahl von Therapieoptionen zur 
Verfügung. Alle haben die Linderung der LUTS Symptome als Therapieziel. 
Das Spektrum reicht von anfänglichem Beobachten, ob sich die Beschwerden 
von selbst bessern, über Medikamente bis hin zu zahlreichen Operationsver-
fahren, bei denen die Prostata teilweise entfernt wird. Die Prostatakapsel 
bleibt immer bestehen. Transurethrale Resektion der Prostata (TURP) gilt aber 
als die Standardmethode zur Behandlung des BPH. 
gutartige 
Prostatahyperplasie 
(BPH):  
 
Vergrößerung der 
Prostata verursacht  
mäßige bis schwere 
Symptome des unteren 
Harntraktes (LUTS) 
 
Harndrang, Blasen- 
entleerungsstörungen 
etc. 
LUTS Schweregrad: 
gemessen mit IPSS 
Prävalenz:  
42 % Männer 51-60 J, 
82 % 71-80 J 
nicht alle 
symptomatisch 
österr. Umfrage zu 
LUTS: 9,1 % aller 
Männer jeglichen Alters  
 
 
Standarddiagnostik: 
 
Stufen-/ 
Differentialdiagnostik 
Vielzahl von 
Therapieoptionen  
 
TURP gilt als 
Standardmethode 
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2015 wurde TURP 5.983 mal und die offene Prostatektomie 150 mal  
in österreichischen Spitälen abgerechnet. 
Beschreibung der Technologie  
Die Prostata-Arterie-Embolisation (PAE) ist eine minimal-invasive Alterna-
tive zur chirurgischen Resektion. Die PAE zielt darauf ab, die Prostata zu 
schrumpfen, anstatt sie zu entfernen. Bei der PAE wird von einem interven-
tionellen Radiologen über eine Leistenarterie ein dünner Katheter in die Ar-
terie der Prostata eingeführt: mittels einer injizierten Lösung von mikrosko-
pischen Partikeln (Durchmesser 80-500 µm) werden die kleinen Äste dieser 
Arterie dauerhaft verschlossen, indem die Partikel die Blutversorgerung der 
Prostata mechanisch blockieren, was ein Schrumpfen der Prostatazellen zur 
Folge hat: Die Verringerung der Blutversorgung führt zu einer ischämischen 
Nekrose, wodurch die Drüsen im Laufe der Zeit erweichen und schrumpfen.  
Vier verschiedene Arten von Embolisationspartikeln, die bei er PAE verwen-
det werden können, verfügen über eine Europäische Marktzulasssung (CE-
Mark), keine jedoch eine US-amerikanische (FDA-)Zulassung. Die Partikeln 
unterscheiden sich in Größe, Form und Material, arbeiten aber alle mit den 
gleichen biomechanischen Prinzipien.  
Tabelle: Characteristika von Embolisationspartikeln zur Behandlung der BPH 
Produkt 
Charakteristika 
Embozene™ 
Microspheres Bead Block® 
Embosphere® 
Microspheres 
PVA Foam 
Embolisation Particles 
Hersteller Boston Scientific 
Corporation* 
Biocompatibles UK Ltd Merit Medical 
Systems Inc 
Cook Medical 
Material HydroGel core with 
Polyzene-F coating 
Polyvinyl alcohol 
hydrogel 
Trisacryl with 
gelatin 
Polyvinyl alcohol 
Form Spherical particles Spherical particles Spherical particles Non-spherical particles 
Durchmesser (µm) 100- 400 100–300, 300-500 100–300, 300-500 90–180, 180–300 
CE Mark Ja, November 2005, 
erneuert Oktober 2015 
Ja, November 2003, 
erneuert Dezember 2014 
Ja, März 2013 Ja, Mai 2013 
FDA Zulassung Nein Nein Nein Nein 
* Formerly manufactured by CeloNova Biosciences, Inc. 
BPH = benign prostatic hyperplasia; FDA = Food and Drug Administration; PVA = polyvinyl alcohol; UK = United Kingdom. 
 
Methoden 
Im folgenden Bericht gingen wir der folgenden Frage nach: Ist PAE im Ver-
gleich zur chirurgischen Resektion (TURP oder offene Prostatektome) bei 
Patienten mit BPH mit mäßigen bis schweren LUTS sicherer bezüglich un-
erwünschter Ereignisse und wirksamer in Bezug auf Veränderungen in Inter-
national Prostate Symptom Scores (IPSS), International Index of Erectile Function 
(IIEF) Score und Lebensqualität Scores?  
Zur Beantwortung der Forschungsfragen, wurde eine systematische Literatur-
suche in vier Datenbanken durchgeführt (Medline via Ovid, Embase, Coch-
rane Library, CRD-Database). Ergänzend erfolgten eine Suche in Studienre-
gistern und eine Studienanfrage bei den Herstellern. Die Daten der entschei-
dungsrelevanten Endpunkte wurden aus den einzelnen Studien zusammen-
gefasst und nach GRADE (Grading of Recommendations Assessment, Devel-
opment and Evaluation) bewertet. Die Studienauswahl, Datenextraktion so-
wie die Bewertung der methodischen Qualität der Studien wurde von zwei 
Autorinnen unabhängig voneinander durchgeführt. 
LKF-Abrechnung 2015 
Prostata-Arterie-
Embolisation (PAE): 
minimal-invasive 
Methode  
 
mittels mikroskopischer 
Partikel wird die 
Blutversorgung der 
Prostata reduziert, diese 
schrumpft in Folge 
vier unterschiedliche 
Embolisations-Partikel 
verfügbar: CE Mark 
keine FDA Zulassung 
Fragestellung  
systematische 
Literatursuche in  
4 Datenbanken; 
Anfrage bei den 
Herstellern; 
Datenextraktion und  
-bewertung durch  
2 AutorInnen 
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Klinische Wirksamkeit und Sicherheit 
Die folgenden Endpunkte wurden für die Bewertung als entscheidend defi-
niert, um eine Empfehlung zur Wirksamkeit von PAE abzuleiten: gesund-
heitsbezogene Lebensqualität Scores (HRQoL), IPSS, IIEF und Krankheits-
progression.  
Die folgenden Endpunkte wurden für die Bewertung als entscheidend defi-
niert, um eine Empfehlung zur Sicherheit von PAE abzuleiten: (Schwerwie-
gende) Unerwünschte Ereignisse und Prozedur-bedingte Mortalität.  
 
Ergebnisse  
Verfügbare Evidenz 
Insgesamt konnten drei vergleichende Studien identifiziert werden, die zur 
Beurteilung der Wirksamkeit herangezogen wurden: Sie verglichen die PAE 
mit der transurethralen Resektion der Prostata (TURP) oder mit der offenen 
Prostatektomie. Für die Beurteilung der Sicherheit wurden auch Beobach-
tungstudien (einarmige-Studien mit mindestens 150 Teilnehmern) und ver-
gleichende Studien (mit unterschiedlichen Partikeln und Patientenpopulatio-
nen) herangezogen. 
Es konnten zwei RCTs, die PAE mit TURP (n = 144) verglichen, und eine 
Matched-Pairs-Studie, in der PAE mit der Prostatektomie (n = 160) vergli-
chen wurde, eingeschlossen werden. Zusätzlich zu diesen Studien wurde ein 
RCT, der PAE-Partikelgrößen verglich, zwei nicht-randomisierte Studien, die 
verschiedene Patientenpopulationen verglichen und zwei einarmige Studien 
für die Sicherheitsergebnisse herangezogen werden. Die zusätzlichen Studien 
umfassten insgesamt 1.168 Patienten.  
In allen eingeschlossenen Studien (mit nur einer Ausnahme) wurden Patien-
ten mit schweren Symptomen (IPSS ≥ 18) behandelt. Das Durchschnittsal-
ter aller Patienten lag zwischen 63 und 73 Jahren (in den Studien zur Wirk-
samkeitsbeurteilung) und zwischen 63 und 83 Jahren (in den Studien zur 
Sicherheitsbeurteilung).  
Klinische Wirksamkeit  
Die Stärke der Evidenz für die Wirksamkeit von PAE im Vergleich zu TURP 
war niedrig. Die eingeschlossenen RCTs machten widersprüchliche Aussa-
gen in Bezug auf Verbesserungen bei IPSS und HRQoL nach 12 Monaten. 
Die größere Studie (n = 114) berichtete keine signifikanten Unterschiede zwi-
schen PAE und TURP nach 12 oder 24 Monaten, während die kleinere Stu-
die (n = 30) TURP nach 12 Monaten in Bezug auf IPSS, HRQoL und IIEF 
begünstigte. Die Progression der Krankheit ist ein seltenes Ereignis und es 
kann deshalb kein Ergebnis aus den zwei Studien abgeleitet werden. Daten 
zu langfristigen (> 24 Monate) Ergebnissen liegen keine vor.  
Die Stärke der Evidenz für die Wirksamkeit von PAE im Vergleich zur offe-
nen Prostatektomie war ebenfalls niedrig. Die Matched-Pairs Studie berich-
tet für die offene Prostatektomie eine signifikant größere Verbesserung im 
IPSS (-19,04 vs. -13,58, P < 0,01) nach 12 Monaten im Vergleich zur PAE. 
Auch in dieser Studie gilt, dass die Progression der Erkrankung ein seltenes 
Ereignis ist und keine Schlussfolgerungen abgeleitet werden können.  
Endpunkte 
Wirksamkeit: 
HRQoL, IPSS, IIEF 
Endpunkte Sicherheit: 
Mortalität, AE, SAE 
Wirksamkeit: nur 
vergleichende Studien 
 
Sicherheit: auch 
Beobachtungsstudien 
> 150 Pts. 
Wirksameit:  
2 RCTs (n = 144)  
1 matched-pairs Studie 
(n = 160) 
Sicherheit: zusätzlich:  
2-einamige Studien + 
3 weitere vergleichende 
Studien (n = 1.168) 
 
Patientencharakteristika 
Schweregrad: IPSS ≥ 18 
Alter: 63-73/83 J 
PAE vs TURP: 
niedrige Stärke der 
Evidenz  
 
widersprüchliche 
Ergebnisse in 2 RCTs 
PAE vs OP: 
niedrige Stärke  
der Evidenz  
signifikant bessere 
Ergebnisse in IPSS und 
IIEF zugunsten von OP 
Zusammenfassung 
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Sicherheit  
Die Stärke der Evidenz für die Sicherheit von PAE im Vergleich zu TURP 
und offener Prostatektomie war moderat. Ein RCT fand bei PAE signifikant 
mehr unerwünschte Ereignisse als bei TURP, während die Matched-Pair-Stu-
die (niedrige Evidenz) deutlich weniger unerwünschte Ereignisse für PAE im 
Vergleich zu offener Prostatektomie berichtete. Es gab keine berichteten Fäl-
le von peri-operativer Mortalität in den eingeschlossenen Studien. Schwerwie-
gende Nebenwirkungen waren selten und beinhalteten einen Fall von Blasen-
wand-Ischämie und acht technische oder klinische Komplikationen über die 
gesamte Sicherheitspopulation (n = 1.472).  
Die in allen Studien am häufigsten berichteten Nebenwirkungen, die mit PAE 
assoziiert waren, waren geringfügig, einschließlich Brennen/Schmerzen beim 
Urinieren (10,2 % bis 100,0 %), akute Harnverhaltung (8,6 % bis 30,8 %), Blut 
im Urin (0,0 % bis 13,3 %), Blut im Samen (1,25 % bis 11,2 %) und Harnwegs-
infektionen (1,25 % bis 4,8 %).  
Laufende Studien  
Derzeit laufen fünf RCTs zu PAE im Vergleich zu TURP bei Patienten mit 
mäßigen bis schweren LUTS, deren Ende für Februar 2021 geplant ist. Dar-
über hinaus gibt es eine laufenden RCT zu PAE im Vergleich mit medizini-
scher Therapie (ebenfalls mit Ende 2021) und ein RCT zu PAE im Vergleich 
mit Placebo (September 2017). Zusätzlich zu den geplanten RCTs läuft eine 
Register-Studie (n = 300) zum Vergleich PAE, TURP und offene Prostatekto-
mie (September 2017). Die meisten der laufenden Studien sind auf 12-Mo-
nats-Follow-up begrenzt, und füllen damit nicht die aktuelle Evidenzlücke 
zur langfristigen Sicherheit und Wirksamkeit von PAE.  
 
Diskussion und Empfehlung 
Die Stärke der Evidenz zur Abschätzung der Sicherheit und Wirksamkeit der 
PAE ist niedrig. Die verfügbaren RCTs berichteten über widersprüchliche 
Ergebnisse für die wichtigsten Wirksamkeitsendpunkte und die unerwünsch-
ten Ereignisse wurden in den eingeschlossenen Studien sehr unterschiedlich 
erhoben und berichtet. Ein einheitliches System zur Dokumentation oder Be-
wertung der Schwere von unerwünschten Ereignissen war nicht vorhanden. 
Allerdings waren schwere unerwünschte Ereignisse selten. Die Studienpopu-
lationen waren in Bezug auf Symptome, Erkrankung und Demographie weit-
gehend verallgemeinerbar.  
Mittel- bis langfristige Follow-up-Daten zu Sicherheits- und Wirksamkeits-
endpunkten > 12-24 Monate liegen nicht vor. Es ist derzeit unbekannt, ob 
das Injizieren von Embolisationspartikeln in die Prostata-Arterie zu langfris-
tigen Nebenwirkungen führen kann oder gar eine Kontraindikation für eine 
chirurgische Folgeintervention darstellt.  
In den eingeschlossenen Studien kamen verschiedene Medizinproduke zur 
Embolisation zur Anwendung, die sich in Form, Material und Größe unter-
scheiden. Ein RCT verglich die Ergebnisse von Partikeln unterschiedlicher 
Größe und fand keinen signifikanten Unterschied in der Wirksamkeit und 
Sicherheit. Es ist unbekannt, ob Partikelmaterial, -form oder -größe einen 
Einfluss auf die langfristigen Ergebnisse haben.  
PAE vs TURP und OP: 
moderate/niedrige 
Stärke der Evidenz  
 
sehr wenige SAE (n = 8) 
bei 1.472 Pts 
hauptsächlich 
geringfügige AE 
5 RCTs zu PAE vs. TURP 
1 RCT PAE vs. 
medizinische Therapie 
1 RCT PAE vs. Placebo 
1 Registerstudie 
 
nur 12 Monats FU 
geringe Stärke  
der Evidenz und 
widersprüchliche 
Ergebnisse für 
Wirksamkeits- und 
Sicherheitsendpunkte 
 
wenige SAE 
„realistische“ Patienten 
verschiedene 
Medizinproduke  
zur Embolisation:  
keine Evidenz zu 
Unterschieden  
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Die vorliegende Evidenz reicht nicht aus, um zu beweisen, dass PAE [bei er-
wachsenen Patienten mit mäßigen bis schweren LUTS] gleich wirksam, aber 
sicherer ist als der/die Komparator/en TURP und/oder offene Prostatektomie. 
Neue Studienergebnisse aus den laufenden RCTs werden die Beurteilung er-
heblich beeinflussen. Eine neuerliche Evaluierung wird im Jahr 2021 vorge-
schlagen, sofern Ergebnisse aus RCTs vorliegen.  
 
vorliegende Evidenz 
reicht nicht aus  
 
Re-Evaluation 2021 
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1 Scope 
1.1 PICO question 
Is prostate artery embolisation (PAE) in comparison to surgical resection in 
patients with benign prostatic hyperplasia (BPH) with moderate-to-severe 
lower urinary tract symptoms (LUTS) safer concerning adverse events, and 
as effective concerning changes in International Prostate Symptom Scores 
(IPSS), International Index of Erectile Function (IIEF) score, and quality of 
life scores? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Second line treatment of benign prostatic hyperplasia (BPH) with moderate-to-severe 
lower urinary tract symptoms (LUTS). Moderate-to-severe LUTS are defined by an 
International Prostate Symptom Score (IPSS) score of 8 to 35 [1]. 
International classification of diseases (ICD)-10-CM code: N40.1 Benign prostatic 
hyperplasia with lower urinary tract symptoms. 
Contraindications/exclusions: prostate cancer, bladder cancer, neurogenic bladder. 
MeSH Terms: Prostatic Hyperplasia [C12.294.565.500], Lower Urinary Tract Symptoms 
[C23.888.942.343] 
Intervention Prostate artery embolisation (PAE), delivered percutaneously by an interventional 
radiologist. There are several embolisation agents currently available in Europe for PAE, 
including: 
 Embosphere® trisacryl microspheres (Merit Medical Systems Inc, USA) 
 Embozene™ polymer microspheres (Boston Scientific, USA) 
 Bead Block® polyvinyl alcohol hydrogel (Biocompatibles UK Ltd, UK) 
 PVA Foam Embolisation Particles (Cook Medical, USA) 
MeSH Term: Embolisation, Therapeutic [E02.520.360, E02.926.500] 
Control Surgical resection of the prostate by any method, including but not limited to  
trans-urethral resection of the prostate (TURP), and open prostatectomy [2]. 
MeSH Term: Prostatectomy [E04.950.774.860.625] 
Rationale: International guidelines on the recommended use of PAE are not currently 
available, due to the experimental nature of the intervention. Recently published clinical 
trials have investigated PAE as an alternative to surgical resection, as it is more invasive 
than medical therapy [3, 4]. Surgical resection is a second-line therapy for BPH following 
failure of, or intolerance to, medical therapy – or as a first-line therapy in cases of 
absolute indications for surgery [2]. 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
Prostate artery embolisation for benign prostatic hyperplasia 
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Outcomes  
Effectivness Clinical endpoints include changes from pre- to post- treatment measurements: 
 Decrease in Health-related quality of life (HRQoL) scores 
 Decrease in International Prostate Symptom Scores (IPSS) 
 Increase in International Index of Erectile Function (IIEF) scores 
 Disease progression or recurrence requiring re-intervention after 12 months 
Surrogate outcomes include changes from pre- to post- treatment measurements of: 
 Peak urinary flow (Qmax) 
 Post-voiding residual urine volume 
Rationale: BPH primarily affects quality of life (QoL) through LUTS. Therefore, the main 
outcomes of interest are direct meaures of QoL, including IPSS, IIEF and QoL 
questionnaire scores [5, 6]. Surrogate outcomes of QoL related to function are also relevant. 
Safety  Adverse events (including an increase in IPSS or HRQoL, and a decrease in IIEF) 
 Re-intervention rates within 12 months 
 Procedure-related mortality 
Rationale: PAE is claimed to be less invasive than surgical resection. Perioperative and 
long-term adverse events are the main safety outcomes associated with surgical resection 
and PAE, and are therefore the key safety outcomes for this assessment [7]. Procedure-
related mortality is a rare but important outcome of TURP and open prostatectomy 
(0.32% and 0.51% respectively), and is therefore relevant to this assessment [8, 9]. 
Study design  
Effectivness Systematic reviews of randomised and non-randomised controlled trials  
(with an AMSTAR quality score of > 5). In the absence of systematic reviews,  
the following will be included: 
 Randomised controlled trials 
 Prospective non-randomised controlled trials 
Excluded: conference abstracts, narrative reviews, letter to the editor, author response, 
case reports, case series. 
Safety Systematic reviews of randomised and non-randomised controlled trials, and prospective 
case series with > 150 participants (with an AMSTAR quality score of > 5). In the absence 
of high quality systematic reviews, the following will be included: 
 Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective/retrospective single-arm studies with >150 participants 
Excluded: conference abstracts, narrative reviews, letter to the editor, author response, 
case reports, retrospective and prospective single-arm studies with ≤ 149 participants. 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What are prostate artery embolisation and surgical resection? 
B0002 What is the claimed benefit of prostate artery embolisation in relation to surgical resection? 
B0003 What is the phase of development and implementation of prostate artery embolisation  
and surgical resection? 
B0004 Who administers prostate artery embolisation and the surgical resection and in what context 
and level of care are they provided? 
B0008 What kind of special premises are needed to use prostate artery embolisation and surgical resection? 
B0009 What supplies are needed to use prostate artery embolisation and surgical resection? 
A0020 What is the marketing authorisation status of prostate artery embolisation? 
A0021 What is the reimbursement status of prostate artery embolisation? 
 
Health problem and Current Use 
Element ID Research question 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for benign prostatic hyperplasia? 
A0004 What is the natural course of benign prostatic hyperplasia? 
A0005 What are the symptoms and the burden of disease for the patients with benign prostatic 
hyperplasia? 
A0006 What are the consequences of benign prostatic hyperplasia for society? 
A0024 How is benign prostatic hyperplasia currently diagnosed according to published guidelines  
and in practice? 
A0025 How is benign prostatic hyperplasia currently managed according to published guidelines  
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is prostate artery embolisation utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of prostate artery embolisation on mortality? 
D0005 How does prostate artery embolisation affect symptoms and findings (severity, frequency)  
of benign prostatic hyperplasia? 
D0006 How does prostate artery embolisation affect progression (or recurrence) of benign prostatic 
hyperplasia? 
D0011 What is the effect of prostate artery embolisation on patients’ body functions? 
D0016 How does the use of prostate artery embolisation affect activities of daily living? 
D0012 What is the effect of prostate artery embolisation on generic health-related quality of life? 
D0013 What is the effect of prostate artery embolisation on disease-specific quality of life? 
D0017 Was the use of prostate artery embolisation worthwhile? 
Prostate artery embolisation for benign prostatic hyperplasia 
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Safety 
Element ID Research question 
C0008 How safe is prostate artery embolisation in comparison to surgical resection? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of prostate artery embolisation? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0007 Are prostate artery embolisation and surgical resection associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology, health problem and current use 
 Background publications identified in hand search of databases 
 Clinical practice guidelines identified by hand search of databases 
 Documentation provided by the manufacturers 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 9th of December 2016 
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to articles published in English or Ger-
man, no other search limits were applied. After deduplication, overall 375 ci-
tations were screened for inclusion. The specific search strategy employed for 
each database can be found in the Appendix. 
Manufacturers of two embolisation agents (Bead Block and Embozene) sub-
mitted 19 publications, from which no new citations were identified.  
One additional article was found by hand searching reference lists of included 
studies, resulting in overall 376 hits. 
 
 
  
Quellen 
systematische 
Literatursuche in  
4 Datenbanken  
Kontaktaufnahme  
mit Herstellern 
insgesamt  
376 Publikationen 
identifiziert 
Methods 
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2.4 Flow chart of study selection 
Overall 536 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
2-1.  
In total, nine existing systematic reviews on PAE were identified, but were 
subsequently excluded due to limitations related to quality and selection cri-
teria. Quality appraisal scores for the identified reviews are presented in Ta-
ble A-5. Consequently, only primary studies were included in this review. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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(n=64) 
Full-text articles excluded,  
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(n=55) 
 Other study design (n=44) 
 Duplicate sample (n=1) 
 Wrong outcomes (n=1) 
 Full-text not available (n=1) 
 Low quality systematic 
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Studies included in 
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(n=9) 
 RCTs (n=3) 
 NRCTs (n=3) 
 Case-series with  
≥ 150 participants (n=2) 
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2.5 Analysis 
Data from the included studies was systematically extracted into data extrac-
tion tables based on study design and research question (See Appendix Ta-
bles A-1 to A-4). The extracted data were validated for accuracy by an inde-
pendent researcher. Direct evidence of the effect of PAE on quality of life 
outcomes were identified in the search strategy. Therefore, no further analy-
sis of the data was conducted.  
Two independent researchers conducted quality appraisal, with differences 
settled via consensus. Quality appraisal was conducted with different tools, 
depending on study design (see Appendix Tables A-5 to A-8). Systematic re-
views were appraised using the AMSTAR (Assessing the Methodological Qual-
ity of Systematic Reviews) quality appraisal tool [10]. Randomised studies 
were evaluated using the Cochrane Risk of Bias v1.0 tool, and non-random-
ised studies were evaluated using the ROBINS-I tool (formerly the ACRO-
BAT-NRSI tool) [11], as advised by the EUnetHTA Joint Action 2 reports on 
internal validity of randomised [12] and non-randomised studies [11]. Single 
arm case series were evaluated using the Institute of Health Economics check-
list [13]. 
 
2.6 Synthesis 
The research questions were answered in plain text format, with reference to 
GRADE (Grading of Recommendations Assessment, Development and Eval-
uation) evidence tables included in Table 7-1, and the data-extraction tables 
in the Appendices (See Appendix Tables A-1 to A-4) [14]. No quantitative 
analysis of outcomes was performed, due limited number of RCTs (N = 2) 
and the small number of patients included. 
 
Datenextraktion 
Qualitätsbeurteilung 
 
SR: AMSTAR 
RCT: Cochrane Risk  
of Bias v1.0 
nRCT: ROBINS-I 
Zusammenfassung  
der Evidenz:  
 
GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What are prostate artery embolisation (PAE)  
and surgical resection?  
PAE is a minimally invasive alternative to surgical resection, which aims to 
shrink the prostate gland rather than remove it. In PAE, an interventional 
radiologist inserts a catheter into the femoral artery at the top of the leg, and 
guides the catheter to the prostate arteries. A solution of microscopic parti-
cles is injected through the catheter, which mechanically block the prostate 
arteries and partially reduce the blood supply (see Figure 3-1). The reduc-
tion in blood supply induces ischaemic necrosis, causing the gland to soften 
and shrink in size over time [15]. 
 
Figure 3-1: Diagram of PAE microspheres being inserted into the prostate arteries 
through a catheter. (Source: Merit Medical Systems, Inc. [16]) 
There are a number of embolisation agents currently available for PAE, rang-
ing in shape (spherical and non-spherical), material (polyvinyl alcohol, tris-
acryl gelatin, or hydrogel with a proprietary coating), and diameter (80 µm to 
500 µm) [3, 4, 17-22]. While the particle size and materials differ, they all op-
erate under the same biomechanical principle of providing long-term occlu-
sion of the prostate arteries. The characteristics of currently available embo-
lisation agents are outlined in Table 3-1. 
 Surgical treatments for LUTS suggestive of BPH involve the removal of ad-
enomatous prostate tissue, for the relief of symptoms and obstruction. There 
are many methods for ablating adenomatous prostate tissue and de-obstruc-
tion of the prostatic urethra, the most common of which include open pros-
tatectomy and TURP. 
Open prostatectomy involves the surgical removal of obstructive prostate tissue 
through an incision in the lower abdomen. Due to its high level of invasive-
ness, open prostatectomy is usually reserved for patients with very large prosta-
tes, or in concomitant diseases such as bladder diverticulitis, or in whom TURP 
or transurethral holmium or thulium laser enucleation is not possible [2, 5]. 
PAE minimal-invasive  
Methode: Katheter wird 
zur Prostata-Arterie 
eingeführt 
 
mikroskopische Partikel 
injiziert: Teilblockade 
der Blutzufuhr 
 
ischämische Nekrose: 
Drüsen schrumpfen 
Embolisations-Partikel: 
unterschiedlich in Form, 
Größe und Material 
 
aber gleiches 
biomechanisches Prinzip 
chirurgische Therapie 
von LUTS: 
am Gebräuchlichsten: 
TURP 
offene Prostatektomie: 
invasivste Methode 
 
zahlreiche weitere 
Methoden 
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Table 3-1: Characteristics of embolisation agents used to treat benign prostatic hyperplasia 
Device 
characteristics 
Embozene™ 
Microspheres Bead Block® 
Embosphere® 
Microspheres 
PVA Foam 
Embolisation Particles 
Manufacturer Boston Scientific 
Corporation* 
Biocompatibles UK Ltd Merit Medical 
Systems Inc 
Cook Medical 
Material HydroGel core with 
Polyzene-F coating 
Polyvinyl alcohol 
hydrogel 
Trisacryl with 
gelatin 
Polyvinyl alcohol 
Shape Spherical particles Spherical particles Spherical particles Non-spherical 
particles 
Diameter (µm) 
used to treat BPH 
100- 400 100–300, 300-500 100–300, 300-500 90–180, 180–300 
CE Mark Yes, November 2005, 
renewed October 2015 
Yes, November 2003, 
renewed December 2014 
Yes, March 2013 Yes, May 2013 
FDA Approval No No No No 
* Formerly manufactured by CeloNova Biosciences, Inc. 
BPH = benign prostatic hyperplasia; FDA = Food and Drug Administration; PVA = polyvinyl alcohol; UK = United Kingdom. 
 
 
In TURP, a resectoscope is inserted into the penile urethra and forwarded to 
the prostatic urethra, where the adenomatous tissue is removed piece by piece 
(See Figure 3-2). TURP is currently the most common method for prostate 
reduction to treat LUTS suggestive of BPH and obstruction, due to its lower 
level of invasiveness compared to open prostatectomy.  
 
Figure 3-2: Trans Urethral Resection of the Prostate using a resectoscope  
(Source: National Cancer Institute [23]) 
  
TURP: Entfernung von 
adenomatösem Gewebe 
Description and technical characteristics of technology 
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B0002 – What is the claimed benefit  
of prostate artery embolisation in relation to surgical resection? 
Prostate artery embolisation is thought to result in fewer complications and 
adverse events than surgical resection, while providing equivalent improve-
ments in quality of life and symptom relief [24]. As PAE is less invasive than 
resection, it requires less recovery time in hospital, with patients often able to 
return home on the same day as the procedure [15]. 
B0003 – What is the phase of development and implementation  
of prostate artery embolisation and surgical resection? 
PAE was first established in the 1970s as a method for controlling prostate 
bleeding, either due to prostate carcinoma, or perioperative complications [25, 
26]. It was first described as a potential therapy for treating bladder outlet ob-
struction due to BPH in the early 2000s [27], and was first trialled in human 
patients in 2010 [28]. In 2013, PAE was considered an experimental procedure 
by the National Institute of Clinical Excellence (NICE) in the United King-
dom, largely due to the lack of comparative studies with long-term follow-up 
[29]. PAE is currently not included in European or American urology guide-
lines for the treatment of BPH [2,5], but is currently disseminating in clini-
cal practice around the world. 
Both TURP and open prostatectomy are well-established methods for the 
treatment of benign prostatic hyperplasia. Open prostatectomy is a surgical 
treatment for moderate-to-severe LUTS secondary to BPH, first described in 
1894, and is the current standard of care for patients with prostates larger than 
80mL [2, 30]. TURP is currently the most common procedure for treating 
BPH in patients with prostate volume of 30-80mL, due to its lower level of 
invasiveness compared to open prostatectomy [2]. 
 
Administration, Investments, personnel and tools required  
to use the technology and the comparator(s) 
B0004 – Who administers prostate artery embolisation and surgical 
resection and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use prostate artery 
embolisation and surgical resection? 
B0009 – What supplies are needed to use prostate artery embolisation 
and surgical resection? 
Prostate artery embolisation is conducted by a highly skilled interventional 
radiologist in an outpatient setting. The procedure is technically demanding, 
and requires a high degree of expertise. Patients treated with PAE are typi-
cally treated as day-patients, and are able to return home within 4 hours after 
the procedure [20]. In the rare event of a serious adverse event, patients may 
be kept overnight. PAE involves the use of a microcatheter and wire, emboli-
sation agents, local or epidural anaesthesia, and intraoperative fluoroscopy. 
The average procedure time reported in the literature ranges between 70 to 
90 minutes [19, 20, 31], due to the challenging task of placing a catheter in 
the target arteries. As a result, prolonged fluoroscopy exposure may be re-
quired. 
Surgical resection of the prostate is conducted by a urologist in an inpatient 
hospital setting. Due to the invasive nature of surgical resection, patients are 
required to be admitted to hospital for several days in order to aid recovery, 
and manage potential post-surgical adverse events [9]. Surgical equipment 
PAE verspricht weniger 
Komplikationen und AE 
als bei chirurgischen 
Methoden 
PAE seit 1970er 
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PAE:  
intervenioneller 
Radiologe 
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braucht Erfahrung 
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varies depending on the type of procedure. TURP is conducted using a resec-
toscope, while open prostatectomy is conducted using standard surgical equip-
ment. Resection is most commonly conducted under general or epidural an-
aesthesia. 
 
Regulatory & reimbursement status  
A0020 – What is the marketing authorisation status of the technology? 
Four embolisation agents used for PAE have received marketing authorisa-
tion in the European Union: 
1. Embozene™ Microspheres, manufactured by Boston Scientific (Marl-
borough, USA), received an EC Certificate in November 2005, which 
was renewed in October 2015 (CE 425968). The device was approved 
for use in patients with BPH. The manufacturer supplied the EC Cer-
tificate. 
2. Bead Block® polyvinyl alcohol hydrogel, manufactured by Biocompat-
ibles UK Ltd (London, UK), received an EC Certificate (CE 79333) in 
November 2003, updated in December 2014. This device was approved 
for the treatment of BPH. The manufacturer supplied the EC Certifi-
cate. 
3. Embosphere® trisacryl microspheres, manufactured by Merit Medical 
Systems Inc. (South Jordan, USA), received an EC Certificate in March 
2013 for the relief of symptoms related to BPH [32]. 
4. PVA Foam Embolisation Particles, manufactured by Cook Medical 
(Bloomington, USA), received an EC Certificate in May 2013 for the 
treatment of BPH [33]. 
None of the four embolisation agents used for PAE holds a FDA-approval 
(see Table 3-1). 
A0021 – What is the reimbursement status  
of prostate artery embolisation? 
Currently, PAE is not included in the Austrian hospital benefit catalogue, and 
therefore is not reimbursed by the Austrian health care system. 
 
vier unterschiedliche 
Embolisations-Partikel 
mit CE Mark:  
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Österreich 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
The scope of this assessment includes BPH causing moderate-to-severe LUTS. 
Benign prostatic hyperplasia is a non-cancerous growth of the prostate gland, 
leading to different degrees of enlargement in most cases. Benign enlargement 
of the prostate gland, bladder outlet obstruction, and LUTS are independent 
factors, in any combination referred to as “LUTS suggestive of BPH”. The 
symptoms of BPH are classified as voiding, storage or post-micturition prob-
lems [34]. 
Lower urinary tract symptoms suggestive of BPH can be classified as mild to 
severe based on the IPSS, a self-administered patient questionnaire on symp-
toms and quality of life. A score of 8 to 19 is considered moderate LUTS and 
a score of 20 to 35 is considered severe [1]. 
A0003 – What are the known risk factors for benign prostatic hyperplasia? 
The strongest risk factors for BPH are age over 50 years, and obesity. Other, 
weaker risk factors include: race (black men are more likely than Caucasian 
men to have larger prostate volume and more moderate-to-severe LUTS; Asian 
men are less likely than Caucasian and black men to have BPH); higher free 
prostate specific antigen (PSA) levels; heart disease; family history of bladder 
cancer; prostatitis; use of beta-blockers and lack of physical exercise [35, 36]. 
A0004 What is the natural course of benign prostatic hyperplasia? 
Approximately 20 to 30 per cent of patients with BPH experience disease pro-
gression (symptom progression of ≥ 3 points), but the speed and likelihood 
of progression varies greatly between individuals [2, 37, 38]. If left untreated, 
BPH can cause acute urinary tract infections, bladder calculi, bleeding from 
prostatic varicose veins, hydronephrosis and renal failure. Approximately 2.5 
per cent of men with symptomatic BPH who are not treated will develop acute 
urinary retention, and another 6 per cent will require invasive therapy, over 
a 5-year time-frame [39, 40]. Older age, previous diagnosis of BPH or erectile 
dysfunction, and lower high-density lipoprotein cholesterol, testosterone and 
low socioeconomic status have been observed to predict progression of LUTS 
[34]. 
 
Effects of the disease or  
health condition on the individual and society 
A0005 – What are the symptoms and the burden of disease  
or health condition for the patient? 
There are three main categories of LUTS due to BPH, including storage, void-
ing and post-micturition symptoms. Enlargement of the prostate caused by 
BPH can be related to a range of LUTS including [34, 36]: 
 Urinary frequency; 
 Urinary urgency; 
 Nocturia (the need to get up frequently at night to urinate); 
gutartige 
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 Incomplete bladder emptying (the feeling of persistent residual  
urine regardless of the frequency of urination); 
 The need to strain or push to initiate and maintain urination  
to fully evacuate the bladder; 
 Decreased force of stream; 
 Dribbling (the loss of small amounts of urine due to a poor  
urinary stream); 
 Other problems such as pain in the perineum, painful urination  
and blood in the urine. 
A0006 – What are the consequences  
of benign prostatic hyperplasia for society? 
Moderate-to-severe LUTS due to BPH is one of the most common medical 
conditions in men, affecting three in four men over the age of 70 [41]. BPH 
carries a large societal cost, in terms of direct medical treatments, as well as 
indirect losses in daily functioning caused by decreased quality of life [42].  
It is difficult to estimate the overall cost of BPH to society, due to under-diag-
nosis and the absence of available data on disease prevalence and treatments. 
The majority of costs associated with BPH in Austria are related to outpa-
tient care, but the total financial impact is unclear [43]. Estimates of the to-
tal economic burden due to BPH vary greatly in the literature. In the United 
Kingdom, BPH has been estimated to cost £180.8 million in 2008 [44], while 
studies from the United States range between $2.3 to $4 billion in 2006 [41]. 
The burden of BPH is likely to rise in future, as it is strongly associated with 
age [45]. 
 
Current clinical management of the disease or health condition 
A0024 – How is benign prostatic hyperplasia currently diagnosed 
according to published guidelines and in practice? 
The initial assessment of LUTS is conducted by reviewing the patient’s his-
tory, including questions about risk factors, voiding problems (hesitancy, in-
termittency, weak stream, straining, incomplete emptying and post-void drib-
bling) and storage problems (urinary frequency, nocturia and urgency) [2, 6, 
7]. Symptom score questionnaires, such as IPSS, are used during the initial 
assessment to quantify the severity of a patient’s LUTS. If voiding symptoms 
are present, a frequency and volume voiding diary may be used to document 
and clarify symptoms, in order to exclude polyuria [7]. 
Physical examination is also used to identify potential causes of LUTS, through 
bladder palpitation and inspection, and digital rectal examination (DRE) [2, 
6]. The DRE is used to assess anal sphincter tone, estimate the size of the pros-
tate and assess for prostate nodules or rectal masses. Transrectal ultrasound 
may be used to complement DRE, as it is able to provide a more accurate 
measure of prostate volume. Other imaging tests, such as urinary tract and 
renal ultrasound, are only recommended if the patient has one of the follow-
ing [7]:  
 Chronic retention; 
 Recurrent urinary tract infection/haematuria; 
 Renal insufficiency; 
 Urolithiasis; or 
 History of prior urinary tract surgery. 
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Initial evaluations also typically include a urinalysis (assessment of the urine 
for the presence of blood, leukocytes, bacteria, protein or glucose) and prostate 
specific antigen (PSA) testing. PSA testing should only be used in appropri-
ate circumstances: not as a general screening tool, not in men > 75 years and 
not when life expectancy is less than 10 years [2, 6, 7]. Cystoscopy may be 
used in certain cases, and urodynamic studies may be used to demonstrate 
obstruction and to exclude neurogenic bladder disorders [2]. 
The combination of clinical history, physical examination, symptom score 
questionnaires, and testing aims to provide a differential diagnosis of LUTS 
due to BPH, and exclude other potential causes of symptoms, including: over-
active bladder, prostatitis, prostate cancer, urinary tract infection (UTI), blad-
der cancer, neurogenic bladder and urethral stricture. If necessary, biopsy may 
be required to exclude prostate cancer and confirm the diagnosis of BPH. 
A0025 – How is benign prostatic hyperplasia currently managed 
according to published guidelines and in practice? 
The European Association of Urology (EAU) published a clinical practice 
guideline for patients with LUTS including benign prostatic obstruction in 
2016 [2, 6]. In patients with moderate-to-severe LUTS, who are not indicated 
for surgery, symptoms are initially managed with lifestyle advice and medi-
cal therapy. The choice of pharmaceutical depends on the predominant symp-
toms and treatment preferences, and includes [2]: 
 α1-blocker;  
 muscarinic receptor antagonist; 
 5α-reductase inhibitor; 
 phosphodiesterase type 5 inhibitors; or 
 combination therapy. 
Medical therapy and response should be reassessed every 6 to 12 months. Be-
havioural management programmes may also be used in addition to medical 
therapy, to decrease symptoms and improve quality of life [2]. 
Surgical management of LUTS is indicated for patients with an absolute in-
dication for surgery, that have not responded to medical therapy, or do not 
want medical therapy but request active treatment [2]. Absolute indications 
for surgery include intractable urinary retention and renal insufficiency caused 
by benign prostatic obstruction [46]. Relative indications for surgery include 
[2, 46]: 
 moderate-to-severe LUTS (i.e. IPSS score greater than 8);  
 recurrent cystitis; 
 overflow incontinence 
 bladder stones or diverticula; 
 failure or intolerance to medical therapy; 
 recurrent urinary tract infection; and 
 treatment-resistant macroscopic haematuria due to BPH. 
In patients with a low cardiovascular risk, the choice of first-line surgical 
therapy depends on the size of the prostate gland (See Figure 4-1) [2]: 
 < 30mL: transurethral incision of the prostate (TUIP) 
 30-80mL: transurethral resection of the prostate (TURP) 
 > 80mL: open prostatectomy or holmium laser enucleation (HoLEP) 
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Alternative surgical treatments for low-risk patients include transurethral va-
porisation of the prostate (TUVP), transurethral needle ablation (TUNA), la-
ser enucleation, transurethral microwave therapy (TUMT), GreenLight laser 
vaporisation or plasmakinetic enucleation [2, 6]. 
In patients with a high cardiovascular risk, who cannot undergo anaesthesia 
or stop anticoagulant therapy, the surgical options include laser vaporisation, 
laser enucleation, TUMT, TUNA and prostatic sent [2, 6]. 
 
TUIP = transurethral incision of the prostate; TURP = transurethral resection of the prostate;  
TUMT = transurethral microwave therapy; TUNA = transurethral needle ablation; HoLEP = holmium laser enucleation. 
Figure 4-1: Clinical management algorithm for the surgical treatment of moderate-to-severe LUTS  
(Source: EAU Guideline [2])  
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment includes patients with BPH causing 
moderate-to-severe LUTS. Moderate-to-severe LUTS are defined as an IPSS 
of 8 to 35 [47]. Patients with LUTS caused by bladder abnormalities (e.g. blad-
der cancer, neurogenic bladder), or prostate cancer, were excluded from this 
assessment. 
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A0023 – How many people belong to the target population?  
Global estimates of BPH vary depending on how BPH is defined, and whether 
or not it is associated with moderate or severe LUTS [7]. The prevalence of 
histological BPH has been estimated to be 42 per cent of men aged between 
51 and 60, and 82 per cent of men aged between 71 and 80 [48].  
In 2009, a population-based cross-sectional survey of 1,926 Austrian men aged 
15 to 89 years found that 64.6 per cent reported some degree of LUTS [45]. 
Moderate-to-severe LUTS was reported by 9.1 per cent of respondents, reflect-
ing an IPSS score greater than eight, and quality of life described as ‘dissat-
isfied’ or worse. It is important to note that BPH is not the only condition 
that contributes to LUTS. Therefore, this is likely an overestimate of the size 
of the eligible population. 
A0011 – How much is prostate artery embolisation utilised? 
The current and likely utilisation of PAE in Austria is difficult to estimate, 
due to the current stage of development of the intervention. The Diagnosis-
Related Group codes (LKF JG020 TURP, JG030 open prostatectomy, JG040 
laparoscopic prostatectomy) for the main comparators, TURP and prostatec-
tomy, were claimed for 5,983 (TURP), 150 (open prostatectomy) and 22 (lapa-
roscopic prostatectomy) procedures in 2015 respectively. While PAE will not 
replace TURP or open prostatectomy entirely, this is a reasonable estimate 
for the size of the population that may be eligible for PAE therapy in Austria. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 International Prostate Symptom Scores (IPSS) 
 Health-related quality of life scores (HRQoL) 
 International Index of Erectile Function (IIEF) 
 Disease progression or recurrence 
The International Prostate Symptom Score is a 7-question survey instrument 
used to screen for, diagnose and measure the symptoms of BPH [1]. Patients 
are asked to score how frequently they had symptoms of incomplete emptying, 
frequency, intermittency, urgency, weak stream, straining and nocturia for the 
past month, on a scale from 0 (not at all) to 5 (always). Scores are then added 
to give an overall symptom score, whereby 1-7 indicates mild LUTS, 8-19 in-
dicates moderate LUTS, and 20-35 indicates severe LUTS. In the included 
studies clinical success was often defined as an reduction in IPSS score of 3 
to 7 points [21, 22], or a 25 per cent reduction from baseline IPSS [17, 18, 20]. 
A 3-point reduction in IPSS indicates a slight improvement in symptoms, and 
a 5-point reduction indicates a moderate improvement [39]. 
In addition to the symptom-specific questions, the IPSS questionnaire includes 
one question on health-related quality of life caused by the urinary symptoms 
of BPH. The question asks patients how they would feel if they had to spend 
the rest of their life with their current urinary symptoms. Answers are scored 
using a 6-point scale ranging from 0 (delighted) to 6 (terrible) [1]. A reduction 
in baseline QoL score of 1 point, or a score lower than 3 (mixed), was most 
commonly used as a marker for clinical success [17, 18, 20-22]. 
International Index of Erectile Function, is derived from a self-reported ques-
tionnaire of male sexual function [49]. Unlike IPSS, IIEF is not specific to 
BPH; it is a generic score for measuring erectile dysfunction. There are two 
versions of the IIEF instrument, which include either 15 (IIEF) or 5 (IIEF-5) 
questions related to sexual function. The questionnaires ask patients to score 
questions about how they felt over the previous six months in relation to sex-
ual intercourse. Scores for each question range from 1 to 5, and the sum of all 
scores provides the overall IIEF score. An IIEF score ranging from 1 to 7 in-
dicates severe sexual dysfunction, 8 to 11 moderate, and 12 to 16 mild. Min-
imum clinically important differences in IIEF scores were not defined in the 
included studies. 
Disease progression or recurrence was evaluated by symptom recurrence or 
progression significant enough to require intervention more than 12 months 
after the procedure (e.g. an increase in IPSS ≥ 4 points) [50]. 
Surrogate outcomes for health-related quality of life were deemed  
important, but not crucial to derive a recommendation: 
 Peak urinary flow (Qmax) 
 Post-voiding residual urine volume 
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5.2 Included studies 
To evaluate the effectiveness of PAE, we included RCTs and non-randomised 
studies comparing PAE to either TURP or open prostatectomy. Two RCTs 
comparing PAE to TURP [3, 19], and one propensity score matched-pairs 
comparison of PAE compared to open prostatectomy were identified [4].  
Study characteristics 
The RCTs were conducted in China [19] and Portugal [3], and the matched-
pairs trial was conducted in Italy (open prostatectomy group) and Russia 
(PAE group) [4]. None of the included studies reported a financial sponsor 
or relevant conflicts of interest. The length of follow-up ranged between 12 
[3, 4] and 24 months [19]. Long term comparative data for clinical outcomes 
beyond 24 months is not currently available. 
The RCTs that compared PAE to TURP used different embolisation parti-
cles. One RCT used spherical Embosphere Microspheres (Merit Medical Sys-
tems Inc., USA) [3], while the other used non-spherical PVA foam embolisa-
tion particles (Cook Medical, USA) [19]. Both particle types had the same 
average diameter (300 to 500µm). 
Patient characteristics 
In total, there were 144 patients included in the RCTs comparing PAE and 
TURP (72 vs. 72) [3, 19], and 160 patients in the matched-pairs trial com-
paring PAE to open prostatectomy (80 vs. 80) [4]. Of note, the RCT reported 
by Carnevale et al (2016) only included 15 patients in each treatment arm, 
and was unlikely to be sufficiently powered to detect clinically important dif-
ferences in the critical outcomes [3]. In contrast, Gao et al (2014) estimated 
the sample size required to detect a 3-point difference in IPSS with 80% pow-
er and a type I error α < 0.5 [19]. Russo et al (2015) reported their study was 
sufficiently powered, but did not provide a power calculation [4].  
The mean age of participants in each treatment arm was equivalent within 
each study, as well as across included studies (range 63.5 ± 8.7 to 68.4 ± 6.1). 
The included trials reported similar inclusion and exclusion criteria, with the 
exception of symptom severity. One RCT included severe LUTS only (IPSS 
> 18) [3], whereas the other included moderate-severe LUTS (IPSS > 8) 
[19]. As a result, the mean baseline IPSS scores for patients treated with PAE 
(25.3 ± 3.6 vs. 22.8 ± 5.9) and TURP (27.6 ± 3.2 vs. 23.1 ± 5.8) were higher 
in Carnevale et al (2016) compared to Gao et al (2014). 
Detailed patient and study characteristics of the included studies are present-
ed in Table A-1 and Table A-2. 
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5.3 Results 
Treatment effect on mortality of BPH 
D0001 – What is the expected beneficial effect  
of prostate artery embolisation on mortality? 
Mortality is a very rare outcome of BPH [51]. None of the included studies 
reported any cases of overall or disease-specific mortality, in either the PAE 
or prostatectomy groups. 
 
Treatment effect on morbidity of BPH 
D0005 – How does prostate artery embolisation affect symptoms  
and findings (severity, frequency) of benign prostatic hyperplasia? 
This research question was answered using the direct outcomes of IPSS. 
PAE compared to TURP 
In regards to urinary symptoms, both RCTs reported significant improve-
ments in IPSS in both the PAE and TURP groups at 12 months [3, 19]; how-
ever, Gao et al (2014) reported no significant difference between PAE and 
TURP in relation to the change in mean IPSS score at 12 months (-13.8 vs. -
14.1, P > 0.05) or 24 months (-15.6 vs. -16.3 P > 0.05) [19]. In contrast, Car-
nevale et al (2016) reported significantly greater improvements in the mean 
IPSS scores in the TURP group at 12 months (-12.5 vs. -21.5, P < 0.001) [3]. 
There was no significant difference in mean IIEF-5 score between PAE and 
TURP at 12 months (12.6 vs. 16.1, P > 0.05) [3].  
PAE compared to open prostatectomy 
In the matched-pairs trial, open prostatectomy was associated with a signifi-
cantly greater improvement in mean IPSS (-13.58 vs. -19.04, P < 0.01) at 12 
months compared to PAE [4]. 
D0006 – How does prostate artery embolisation affect progression  
(or recurrence) of benign prostatic hyperplasia? 
 No evidence was found to answer this research question. 
 
Function 
D0011 – What is the effect of prostate artery embolisation  
on patients’ body functions? 
Surrogate outcomes for obstruction, peak urinary flow (Qmax) and  
post-voiding residual volume, were used to evaluate this research question.  
PAE compared to TURP 
The RCTs reported conflicting results regarding functional outcomes. The 
larger RCT reported no significant difference in Qmax (+14.3 mL/s vs. +15.8 
mL/s, P > 0.05) or post-voiding residual volume (-107.5 cm3 vs. -100.2 cm3, 
P > 0.05) at 12 months [19]. In contrast, the smaller RCT reported TURP to 
be associated with significantly greater improvements in Qmax (+3.1 mL/s 
vs. +17.4 mL/s, P < 0.0001) and mean post-voiding residual volume (-64.7 cm3 
vs. -70.0 cm3, P = 0.006) at 12 months [3]. 
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PAE compared to open prostatectomy 
In the matched-pairs comparison, open prostatectomy was associated with 
significantly greater improvements in Qmax (+9.29 mL/s vs. +15.97 mL/s, 
P < 0.01) and mean post-voiding residual volume (-45.87 cm3 vs. -58.8 cm3, 
P < 0.01) at 12 months compared to PAE [4]. 
D0016 – How does the use of prostate artery embolisation affect 
activities of daily living? 
Research question D0005 addressed the impact of PAE on sexual function 
and symptoms, in relation to improvements in IPSS. No other evidence was 
found to answer this research question. 
 
Health-related quality of life 
D0012 – What is the effect of prostate artery embolisation  
on generic health-related quality of life? 
No evidence was found to answer this research question. 
D0013 – What is the effect of prostate artery embolisation  
on disease-specific quality of life? 
This research question was assessed using the disease-specific quality of life 
question included in the IPSS questionnaire.  
PAE compared to TURP 
Gao et al (2014) reported a significant improvement in disease-specific qual-
ity of life in both PAE and TURP groups at 12 and 24 months (P = 0.001) 
[19]. However, there was no significant difference between PAE and TURP 
in relation to the change in quality of life at 12 months (-2.9 vs -2.8, P > 0.05) 
or 24 months (-3.2 vs. -3.2, P > 0.05). 
Carnevale et al (2016) reported a significant improvement in disease-specific 
quality of life in both groups at 12 months (P < 0.05) [3]; however, TURP was 
associated with a greater improvement compared to PAE at 12 months (-2.5 
vs -3.7, P = 0.004). 
PAE compared to open prostatectomy 
No evidence was found to answer this research question. 
 
Patient satisfaction 
D0017 – Were patients satisfied with the technology? 
No evidence was found to answer this research question. 
 
PAE vs OP 
signifikant bessere 
Ergebnisse zugunsten 
von OP 
keine Evidenz 
keine Evidenz 
PAE vs TURP 
 
widersprüchliche 
Ergebnisse bei  
disease-specific QoL 
PAE vs OP 
keine Evidenz 
keine Evidenz 
 LBI-HTA | 2017 33 
6 Safety 
6.1 Outcomes 
The following outcome was defined as crucial to derive a recommendation: 
 Adverse events (including minor adverse events, major adverse 
events, decrease in IIEF, and increase in IPSS and HRQoL) 
 Re-intervention rates within 12 months 
 Procedure-related mortality 
In accordance with the EUnetHTA guidelines on Safety outcomes, adverse 
events are defined as “any untoward medical occurrence, unintended disease 
or injury or any untoward clinical signs (including an abnormal laboratory 
finding) in subjects, users or other persons whether or not related to the in-
vestigational medical device” [52]. Adverse events, including total, major and 
minor adverse events, which may occur during the perioperative period or 
during long-term follow-up, are the most common safety issues associated 
with PAE and the comparator interventions. These outcomes are non-spe-
cific in order to be inclusive of all types of adverse events that may be related 
to PAE or surgical resection. The most frequently reported adverse events 
have been highlighted.  
Procedure-related mortality (typically measured at 30 days post-procedure) 
is a rare but potential outcome of TURP and open prostatectomy (0.32% and 
0.51% respectively) [8, 9]. Therefore, this outcome is relevant to a compari-
son of the relative safety of PAE and surgical resection. 
 
 
6.2 Included Studies 
To evaluate the safety of PAE, RCTs, non-randomised studies and prospec-
tive single-arm studies with at least 150 patients were selected for inclusion. 
In addition to the studies described in the Section 5 (Clinical Effectiveness), 
the following studies were identified: 
 One RCT comparing PAE with 100µm particles to 200µm particles 
[17]; 
 Two prospective non-randomised studies comparing PAE in different 
patient groups (age, prostate size) [21, 22]; 
 Two retrospective single-arm studies with more than 150 patients  
[18, 20]. 
Study characteristics 
Three of the additional safety studies were conducted in Portugal [17, 18, 20] 
and two in China [21, 22]. The three studies from Portugal were from the 
same group of authors; however, only one study reported conflicts of interest 
– a key author received a consulting fees from Cook Medical (USA), the man-
ufacturer of the embolisation agent [17, 18, 20]. The remaining studies did 
not report any significant conflicts of interest. 
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The reported follow-up periods ranged between 6 to 78 months, with most 
studies reporting a mean or median follow-up period of between 6 to 24 
months [17, 18, 20-22]. The largest retrospective single-arm study (n = 630) 
reported a median follow-up period of 24 months, with the longest duration 
of observation of 78 months [20]. 
Four studies investigated the PVA particles (Cook Medical, USA) [17, 20-22], 
two used Bead Block (Biocompatibles, USA) [18], and one used the Embo-
zene Microspheres (Boston Scientific, USA) [20]. 
Safety outcomes were recorded variably across studies, resulting in heteroge-
neous reporting of outcomes and adverse event severity. The grading system 
used to evaluate the severity of adverse events included the Clavien–Dindo 
classification system [4, 19, 22], the Society of Interventional Radiology re-
porting criteria [17, 18, 20, 21], or the National Cancer Institute Common 
Toxicity Criteria for Adverse Events [3]. 
Patient characteristics 
The additional studies included a total of 1,168 patients that underwent PAE 
[17, 18, 20-22]. The mean age of patients in the additional safety trials ranged 
between 63.4 to 82.5 years. All of the additional trials included patients with 
severe LUTS (IPSS ≥ 18) that was refractory to medical therapy for at least 
6 months. 
There was overlap between the sample populations of Wang et al (2016) [21] 
and Wang et al (2016) [22], and also Bilhim et al (2013) [18], Bilhim et al 
(2016) [17] and Pisco et al (2016) [20]. These studies reported different anal-
yses on patients recruited during overlapping enrolment periods. 
Patients and study characteristics of the included studies are presented  
in Table A-1 to Table A-4. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is prostate artery embolisation in comparison  
to surgical resection? 
None of the included studies reported any cases of perioperative mortality in 
either the PAE or prostatectomy groups. Specific adverse event rates associ-
ated with PAE studies are presented in Table A-1 to Table A-4. 
PAE compared to TURP 
Safety outcomes could not be pooled, due to variability in the measurement 
and reporting of complications between studies. 
In the larger RCT, PAE was associated with significantly more overall com-
plications compared to TURP (n = 30 of 57 [52.6%] vs. 17 of 57 [29.8%], 
P = 0.03) [19]. There were more major complications in the PAE group (tech-
nical and clinical failures) compared to the TURP group (transurethral resec-
tion syndrome, clinical failure, bladder neck stenosis), but this was not sta-
tistically significant (n = 8 of 57 [14.0%] vs. 4 of 57 [7.0%], P = 0.28). This 
study defined clinical failures as “persisting severe symptoms (decrease in IPSS 
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of ≤ 25%, IPSS ≥ 18, decrease of QoL score by ≤ 1, and QoL score of ≥ 4), and/or 
peak urinary flow increase of less than 2.5 mL and peak urinary flow of 7 mL/sec 
or lower after the procedure” [19].  
PAE was associated with higher rates of minor complications (n = 22 of 57 
[38.6%] vs. 13 of 57 [22.8%], P = 0.1), including post-embolisation syndrome 
(n = 6 of 54 [11.1%] vs 0 of 53 [0.0%], P = 0.038), and acute urinary reten-
tion (n = 14 of 54 [25.9%] vs 3 of 53 [5.7%], P = 0.004). There were no other 
significant differences between study groups. The most commonly reported 
complications associated with PAE were acute urinary retention (n = 14 of 
54 [25.9%]), post-embolisation syndrome (n = 6 of 54 [11.1%]), and clinical 
failure (n = 5 of 53 [9.4%]). Both PAE and TURP were associated with a de-
crease in IIEF score, however this was not statistically significant (-1.7 vs.  
-3.6, P = NR) [3]. 
The smaller RCT reported specific perioperative complications for PAE and 
TURP, but did not conduct a comparison between groups [3]. Overall, 15 PAE 
patients experienced 22 complications, and 15 TURP patients experienced 23 
complications. The authors noted no major complications in the PAE group, 
and one in the TURP group (intraoperative damage to venous sinus and rup-
ture of prostatic capsule, treated successfully with Foley balloon catheter for 
2 hours post-resection to control bleeding). The most commonly reported com-
plications associated with PAE were local pain or moderate urethral burning 
for 3-4 days post-procedure (n = 15 of 15 [100%]), reduced ejaculate (n = 2 of 
15 [13.3%]) and hematuria (n = 2 of 15 [13.3%]). 
In total, 9.4 to 13.3 per cent of patients that underwent PAE and 0.0 to 3.8 
per cent of patients that underwent TURP required re-intervention at or be-
fore 12 months [3,19].  
PAE compared to open prostatectomy 
In the matched-pairs comparison study, PAE was associated with signifi-
cantly fewer minor adverse events (n = 7 of 80 [8.75%] vs. 25 of 80 [26.25%], 
P < 0.05), compared to open prostatectomy [4]. Similarly, PAE was associat-
ed with a small increase in IIEF-5 (i.e. a clinical improvement), while open 
prostatectomy resulted in a significant decrease (+0.68 vs. -4.22, P < 0.01) 
[4]. No patients in either treatment group required re-intervention [4]. 
Safety of PAE from observational trials 
Only one major complication, a case of bladder wall ischaemia treated with 
surgical intervention, was reported in the observational trials [20]. The re-
maining studies reported no serious adverse events. The most consistently re-
ported minor adverse events were hematospermia (range 7.5% to 11.2%) [17, 
18, 20-22], hematuria (range 7.5% to 11.7%) [17, 18, 20-22], and urinary tract 
infection (range: 2.5% to 4.8%) [17, 18, 20]. Specific adverse events are re-
ported in further detail in response to question C0002 and C0005. 
C0002 – Are the harms related to dosage or frequency  
of applying prostate artery embolisation? 
While not related explicitly to “dosage”, one RCT compared the outcomes 
of patients treated with PAE using two different sizes of particles [17]. The 
study did not find any significant differences in complication rates between 
patients treated with 100µm or 200µm particles. The most commonly reported 
adverse events were irritative voiding (n = 12 of 40 [30.0%] vs. 16 of 40 [40.0%], 
P > 0.99), dysuria (n = 8 of 40 [20.0%] vs. 9 of 40 [22.5%], P > 0.99), and he-
matospermia (n = 3 of 40 [7.5%] vs. 2 of 40 [5.0%], P > 0.99). 
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The reported radiation dose associated with PAE ranged between  
1130.5 ± 267.1 dGy/cm2 [19] and 2401 dGy/cm2 (range: 655-9202) [18]. 
C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
No evidence was found to answer this research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of prostate artery embolisation? 
A non-randomised comparison of PAE in different age groups reported that 
patients aged 75 years or older experienced significantly more urethral burn-
ing (n = 10 of 52 [19.2%] vs. 12 of 105 [11.4%], P = 0.027), and acute urinary 
retention (n = 16 of 52 [30.8%] vs. 9 of 105 [8.6%], P = 0.031) compared to 
patients aged under 75 years [22]. There was no significant difference in IIEF 
score from baseline to 12 months in either group. 
A non-randomised comparison of PAE in patients with different sized pros-
tates reported that patients with a prostate volume greater than 80mL re-
ported significantly more urethral burning (n = 10 of 60 [16.7%] vs. 5 of 49 
[10.2%], P = 0.04) and acute urinary retention (n = 17 of 60 [28.3%] vs. 5 of 49 
[10.2%], P = 0.02) compared to patients with prostate volume between 50mL 
and 80mL [21]. 
There were no significant differences reported for other complications  
in either study. 
C0007 – Are prostate artery embolisation and  
surgical resection associated with user-dependent harms? 
No evidence was found to answer this research question. 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [14] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the difference. 
A more detailed list of criteria applied can be found in the recommendations 
of the GRADE Working Group [14].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1, Table 7-2 and Table 7-3.  
Overall the strength of evidence for the effectiveness of PAE in comparison 
to TURP is low. The strength of evidence for the effectiveness of PAE in com-
parison open prostatectomy is moderate. The strength of evidence for the 
safety of PAE in comparison to TURP open prostatectomy is moderate. 
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Table 7-1: Evidence profile: effectiveness and safety of PAE compared to TURP 
No. of 
studies/patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Efficacy – PAE vs. TURP 
Mean change in quality of life (QoL) score at 12 months* 
2/144 [19] [3] RCT -2.9 vs. -2.8, P > 0.05 [19] 
-2.5 vs. -3.7, P = 0.004 (favours TURP) [3] 
-1 A B -1 direct -1 C Low 
Mean change in International Prostate Symptom Score (IPSS) at 12 months* 
2/144 [19] [3] RCT -13.8 vs. -14.1, P > 0.05 [19] 
-12.5 vs. -21.5, P < 0.001 (favours TURP) [3] 
-1 A B -1 direct -1 C Low 
Symptom recurrence or progression requiring re-intervention after 12 months 
NR 
Safety – PAE vs. TURP 
Major complications (total) 
2/144 [19] [3] RCT 8 (14%) vs. 4 (7%), P = 0.3 [19] 
0 (0%) vs. 2 (13.3%), P = NR [3] 
-1 A B no important 
inconsistency 
direct -1 C Moderate 
Re-intervention within 12 months 
1/114 [19] RCT 9.4% to 13.3% vs. 0.0% to 3.8% (P = NA) no serious limitation -1 direct no Moderate 
Mean change in International Index of Erectile Function (IIEF) score at or before 12 months 
1/30 [3] RCT -1.7 vs. -3.6, P = NR (favours PAE) -1 B NA direct -1 C Low 
Minor complications (total) 
1/114 [19] RCT 22 (38.6%) vs. 13 (22.8%), P = 0.1 -1 A NA direct no Moderate 
Minor complications – hematospermia 
1/30 [3] RCT 1 (6.7%) vs. 0 (0%), P = NR -1 B NA direct -1 c Low 
Minor complications – hematuria 
2/244 [19] [3] RCT 
RCT 
0 (0%) vs. 4 (7.5%), P = 0.12 [19] 
2 (13.3%) vs. 1 (6.7%), P = NR [3] 
-1 A B no important 
inconsistency 
direct -1 C Moderate 
Minor complications – urinary tract infection 
1/114 [19] RCT 1 (1.9%) vs. 2 (3.8%), P = 0.99 -1 A NA direct no Moderate 
* Reported P values were for the between group comparison at 12 months. Baseline scores were equivalent between groups. 
A Overall risk of bias was scored “High” due to unclear allocation concealment, and unadjusted confounding due to additional treatments before or after the intervention. 
B Overall risk of bias was scored “High” due to unclear randomisaton method, unclear allocation concealment, unclear patient and physician blinding, unclear selective reporting,  
and differences between groups at baseline in relation to Qmax, bladder contractility and prostate volume. 
C Very small patient numbers in each treatment arm in [3] 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency  
Indirectness: 0: direct, no uncertainty  
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Table 7-2: Evidence profile: efficacy and safety of PAE compared to open prostatectomy 
No. of 
studies/patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Efficacy – PAE vs. Open Prostatectomy 
Mean change in quality of life (QoL) score at 12 months 
NR 
Mean change in International Prostate Symptom Score (IPSS) at 12 months 
1/160 [4] nRCT -13.58 vs. -19.04, P < 0.01 (favours TURP) no serious limitation NA direct -1 A Low 
Symptom recurrence or progression requiring re-intervention after 12 months 
NR 
Safety – PAE vs. Open Prostatectomy 
Major complications (total) 
1/160 [4] nRCT 0 (0.0%) vs. 3 (3.75%), P = NR no serious limitation NA direct -1 A Low 
Re-intervention within 12 months 
1/160 [4] nRCT No patients in either arm required re-intervention no serious limitation NA direct -1 A Low 
Mean change in International Index of Erectile Function (IIEF) score at 12 months 
1/160 [4] nRCT +0.68 vs. -4.22, P < 0.01 (favours PAE) no serious limitation NA direct -1 A Low 
Minor complications (total) 
1/160 [4] nRCT 7 (8.75%) vs. 21 (26.25%), P < 0.05 (favours PAE) no serious limitation NA direct -1 A Low 
Minor complications - hematospermia 
1/160 [4] nRCT 1 (1.3%) vs. 0 (0.0%), P = NR no serious limitation NA direct -1 A Low 
Minor complications – hematuria 
1/160 [4] nRCT 0 (0.0%) vs. 4 (5.0%), P = NR no serious limitation NA direct -1 A Low 
Minor complications – urinary tract infection 
1/160 [4] nRCT 1 (1.3%) vs. 3 (3.8%), P = NR no serious limitation NA direct -1 A Low 
A This study was conducted in two different countries (Italy and Russia), so while patients were matched with propensity scores, it is difficult to determine  
whether or not the clinical scenario in which patients were treated was comparable. 
Nomenclature for GRADE table: 
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial) 
Indirectness: 0: direct, no uncertainty  
Other modifying factors: -1: study design 
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Table 7-3: Evidence profile: safety of PAE from observational trials 
No. of 
studies/patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Safety - PAE 
Major complications 
1/630 [20] Prospective case series Bladder wall ischemia: 1 (0.2%) -1 A NA direct no Low 
Minor complications – total 
NR 
Minor complications – hematospermia 
5/1168 [17,18,20-22] Cohort studies and  
prospective case series 
Range 7.5% to 11.2% no serious limitation No important 
inconsistency 
-1 B -1 C Very low 
Minor complications – hematuria 
5/1168 [17,18,20-22] Cohort studies and  
Prospective case series 
Range: 7.5% to 11.7% no serious limitation No important 
inconsistency 
-1 B -1 C Very low 
Minor complications - urinary tract infection 
3/856 [17,18,20] Cohort studies and  
Prospective case series 
Range: 2.5% to 4.8% no serious limitation  No important 
inconsistency 
-1 B -1 C Very low 
A Single arm case series design. No additional modifying factors were applied. 
B The research questions targetted specific populations (i.e. varying prostate sizes, older vs. younger age) and particle sizes that may not reflect clinical practice. 
C There was considerable sample overlap between two pairs of studies (Wang and Wang, Bilhim and Pisco). 
Nomenclature for GRADE table: 
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency  
Indirectness: 0: direct, no uncertainty; -1: some uncertainty  
Other modifying factors: -1: imprecise data 
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8 Discussion 
Benign prostate enlargement is a significant contributor to the overall burden 
of disease in men over the age of 50. PAE is a novel method for treating the 
symptoms related to BPH, by reducing the blood supply to the prostate gland 
and causing it to shrink over time. Currently, at least four embolisation agents 
have received market approval in the European Union (i.e. CE mark) for the 
treatment of BPH; however, none of these devices have received approval by 
the United States FDA for this indication. In this review, we sought to iden-
tify the current evidence for the safety and effectiveness of PAE at treating the 
symptoms of BPH, compared to existing therapies – TURP and open prosta-
tectomy. 
 
Interpretation of findings 
Study quality, validity and overall level of evidence 
The overall level of evidence for the estimates of effectiveness of PAE was low.  
The RCTs that investigated PAE compared to TURP had a high risk of bias 
due to small patient numbers, inadequate or unclear randomisation, lack of 
allocation concealment, and lack of blinding for both the patients and treat-
ing physicians [3, 19]. These RCTs reported conflicting results for the main 
effectiveness outcomes, which are not easily explained by differences in study 
design or inclusion criteria. One of the included RCTs was claimed to be ad-
equately powered to detect clinically important differences in effectiveness 
outcome, but not rare outcomes such as major adverse events [19]. The other 
RCT was inadequately powered to detect differences in effectiveness or safety 
outcomes, with only 15 patients in each treatment arm [3], but reported sig-
nificant differences between TURP and PAE nonetheless. 
The matched-pairs comparison of PAE and open prostatectomy was of low 
quality, limited mainly by a lack of blinding of clinicians and patients [4].  
The remaining trials that were included for safety only, including one RCT, 
four non-randomised studies and two single-arm studies, had a high risk of 
bias. This was largely due to significant differences between groups at base-
line, and missing follow-up data.  
Due to the inconsistent nature in which adverse events rates were reported 
across the included studies, it is difficult to provide strong recommendations 
for the likely adverse event rates associated with PAE. A consistent system for 
recording or rating the severity of adverse events was not present. As a result, 
it is currently unclear which adverse events are most likely to occur following 
treatment with PAE, and the rate at which they are likely to occur; however, 
severe adverse events were rare. Notably, there appears to be significant over-
lap between the study populations of Wang et al (2016) and Wang et al (2016) 
[21, 22], as well as Pisco et al (2016), Bilhim et al (2013) and Bilhim et al (2016) 
[17, 18, 20]. As a consequence of this overlap, there may be substantial dupli-
cation of data for the reported safety outcomes. 
Long-term follow-up data of safety and effectiveness outcomes beyond 12-24 
months were limited. It is currently unknown if the effects of PAE are sus-
tained, or if placement of PAE particles may lead to long-term adverse events 
beyond 24 months. 
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Factors that may influence the external validity 
The majority of included studies enrolled patients with an IPSS ≥ 18, while 
one RCT from China used a cut-off for IPSS ≥ 8 [19]. Current European guide-
lines for TURP and open prostatectomy state that comparator interventions 
are indicated for patients with moderate-to-severe LUTS, but it is unclear 
what thresholds are used to select patients for surgical treatments in Austri-
an clinical practice [2]. Although IPSS scores are used to triage patients for 
surgery, ultimately the decision to perform surgery is subjective, and is based 
on the patient’s bother from symptoms. Other than this issue, patient selec-
tion and baseline demographic were reasonably consistent across the includ-
ed studies, and reflect the intended population in clinical practice (i.e. con-
traindication or failure of medical therapy, symptoms not related to bladder 
or cancer, mean age 62.7 to 72.5 years).  
Different embolisation agents were used in the included studies, including 
particles with a range of shapes, materials, and sizes. One RCT that compared 
outcomes of different sized particles found no significant difference in effec-
tiveness or safety [17]. No direct evidence was identified to inform whether 
particle shape or material impact long-term outcomes.  
The comparators, TURP and open prostatectomy, were equivalent to existing 
therapies for PAE currently used in clinical practice. There was limited evi-
dence from European populations; one trial was conducted in Italy, and two 
were conducted in Portugal. The remaining trials were conducted in China, 
Brazil and Russia. The issues affecting the applicability of the current evi-
dence base for PAE to the Austrian context are presented in Table A-9. 
Relevance of the outcomes assessed  
to the potential patient-relevant benefits 
The effectiveness outcomes included in this review directly measured the im-
pact of PAE on disease-related quality of life. The main effectiveness end-
points – IPSS, IIEF and HRQoL – were valid, and measured and reported in 
a consistent way. However, all three of these outcomes are measured with us-
er questionnaires, which involve a level of subjectiveness; however, IPSS has 
been demonstrated to be a valid and reliable tool for measuring the severity 
and impact of LUTS on quality of life [1]. 
Evidence gaps and ongoing studies 
There is currently no long-term follow-up data for PAE relative to TURP or 
open prostatectomy beyond 24 months. It is also unclear if PAE is a contrain-
dication for future surgery, due to the potential to dislodge the embolisation 
particles. Several ongoing studies, identified in Table A-10 to Table A-13, will 
provide additional data for the safety and effectiveness of PAE compared to 
TURP, medical therapy, and placebo; however, these comparative trials are 
planned to have up to 24 months follow-up, and as such will not fill this gap in 
the existing evidence. Only one, small (n = 50), single arm trial has a planned 
follow-up time greater than 24 months. 
The inclusion criteria for this review excluded single-arm studies with less 
than 150 patients. It may be possible that case series studies with less than 
150 patients, but with more than 24 months follow-up may exist to provide 
evidence for the long-term safety of PAE; however, such studies would be con-
sidered a very low level of evidence, and are likely to be underpowered to de-
tect rare adverse events. 
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Conclusion 
Although many systematic reviews have investigated the safety and effective-
ness of PAE for the treatment of BPH, there is limited primary data on its 
long-term clinical effectiveness and safety compared to existing therapies. The 
current evidence base comparing PAE to TURP includes two RCTs, with a 
total of 144 patients, which reported conflicting results. One additional trial 
of 160 patients compared PAE to open prostatectomy, which reported inferi-
or effectiveness outcomes in the PAE group, but fewer complications. 
Concerns have been raised about the long-term safety of PAE, particularly in 
relation to the migration of embolisation particles, necrosis of surrounding tis-
sues, and prolonged radiation exposure [53]. To date, these concerns have not 
been sufficiently addressed in the existing clinical trial data, due to the high-
ly variable nature in which adverse events have been measured and reported. 
While the vast majority of adverse events associated with PAE are mild, the 
incidence of rare but severe complications is unclear. 
Prostate artery embolisation might reasonably fill a small gap in current clin-
ical practice for patients with medically refractory BPH, moderate-to-severe 
LUTS, and who cannot or will not have surgery. In particular, men may choose 
to undergo PAE in order to minimise the potential negative impacts on sex-
ual function associated with surgery. These patients have limited treatment 
alternatives; however, given the current status of the evidence for PAE, it is 
not recommended as an alternative to current therapies to treat BPH. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove, that prostate artery emboli-
sation [in adult patients with moderate-to-severe LUTS] is as effective, but 
safer than the comparators TURP and open prostatectomy. New study results 
will potentially influence the effect estimate. 
The re-evaluation is recommended in 2021, after which time several ongoing 
clinical trials will be completed – noting that these trials will not provide ad-
ditional long-term (i.e. >24 months) data on safety or effectiveness outcomes. 
 
 
 
keine Evidenz, dass 
gleich wirksam wie 
TURP  
Re-valuation 2021 
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Appendix 
Evidence tables of individual studies 
included for clinical effectiveness and safety 
Table A-1: Prostate artery embolisation: Results from randomised controlled trials of PAE compared to TURP 
Author, year Gao et al, 2014 [19] Carnevale, 2016 [3] 
Country China Brazil 
Sponsor Not stated Not stated 
Intervention Unilateral or bilateral PAE with 355-500µm 
polyvinyl alcohol microspheres  
(Ivalon; Cook Medical, USA) 
Unilateral PAE with 300-500µm  
tris-acryl gelatin microspheres  
(Embosphere; Merit Medical, USA) 
Comparator TURP under epidural anaesthesia TURP under epidural anaesthesia 
Study design Prospective randomised controlled trial Prospective randomised controlled trial 
Number of patients 
(Int vs. Co) 
57 vs. 57 15 vs. 15 
Population Patients with moderate-severe LUTS 
secondary to BPH 
Patients with severe LUTS secondary to BPH 
Inclusion criteria IPSS >7; failed medical therapy with 2-week 
washout period; prostate volume 20-100mL; 
peak urinary flow <15mL/sec;  
written informed consent 
Age >45 years; IPSS >19; symptoms 
refractory to medical therapy for at least  
6 months; prostate volume between 30 and 
90cm3 on magnetic resonance imaging; 
bladder obstruction confirmed by 
urodynamic examination 
Exclusion criteria Detrusor hyperactivity or hypocontractility 
at urodynamic study; urethral stricture; 
prostate cancer; diabetes mellitus; previous 
prostate, bladder neck and urethral surgery 
Renal failure; bladder calculi or diverticula; 
suspected prostate cancer; urethral stenosis; 
neurogenic bladder disorders 
Mean age of patients 
(yrs)  
67.7 ± 8.7 vs. 66.4 ± 7.8, P = 0.4 63.5 ± 8.7 (range 46-75) vs.  
66.4 ± 5.6 (range 55-78), P = 0.06 
Follow-up 1, 3, 6, 12, and 24 months 
Mean 22.5 months 
12 months (all patients) 
Loss to follow-up,  
n (%) 
6 months: 1 (1.8) vs. 2 (3.5) 
12 months: 1 (1.8) vs. 1 (1.8) 
NR 
Outcomes 
Efficacy 
Mean QoL score  
(lower is better) 
Baseline: 4.8 vs. 4.6, P > 0.05 
1 month: 3.7 vs. 2.8, P = 0.0001 
3 months: 2.9 vs. 2.3, P = 0.0001 
6 months: 2.2 vs. 2.3, P > 0.05 
12 months: 1.9 vs. 1.8, P > 0.05 
24 months: 1.6 vs. 1.4, P > 0.05 
Baseline: 4.7 ± 0.6 (4-6) vs.  
4.6 ± 0.8 (4-6), P > 0.05 
12 months: 2.2 ± 1.2 (range 1-4) vs.  
0.9 ± 1.4 (range 0-4), P = 0.004 
Mean IPSS 
(lower is better) 
Baseline: 24.7 vs. 24.3, P > 0.05 
1 month: 19.2 vs. 13.7, P = 0.0001 
3 months: 15.6 vs. 11, P = 0.0001 
6 months: 12.8 vs. 11.3, P > 0.05 
12 months: 10.9 vs. 10.2, P > 0.0s5 
24 months: 8.7 vs. 8.4, P > 0.05 
Baseline: 25.3 ± 3.6 (19-30) vs.  
27.6 ± 3.2 (20-34), P > 0.05 
12 months: 12.8 ± 8.0 (range 2-27) vs.  
6.1 ± 8.6 (range 0-27), P < 0.001 
Mean IIEF score  
(higher is better) 
NR Baseline: 14.3 ± 6.8 (0-21) vs.  
12.5 ± 6.6 (0-21), P > 0.05 
12 months: 12.6 ± 7.7 (range 0-21) vs.  
16.1 ± 5.7 (range 5-12), P = NR 
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Author, year Gao et al, 2014 [19] Carnevale, 2016 [3] 
Symptom  
recurrence requiring  
re-intervention, n (%) 
5 (9.4%) vs. 2 (3.8%), P = 0.262 2 (13.3%) vs. 0 (0.0%), P = NR 
Mean Qmax (mL/s) 
(higher is better) 
Baseline: 7.8 vs. 7.3, P > 0.05 
1 month: 13.1 vs. 18.2, P = 0.0001 
3 months: 17.3 vs. 21.4, P = 0.0001 
6 months: 21.5 vs. 23.7, P > 0.05 
12 months: 22.1 vs. 23.1, P > 0.05 
24 months: 21.5 vs. 22.1, P > 0.05 
Baseline:7.0 ± 3.6 (2.9-13.7) vs.  
9.7 ± 3.8 (5.0-18.0), P = 0.05 
12 months: 10.1 ± 6.5 (range 2-25) vs.  
27.1 ± 8.7 (range 12-45), P < 0.0001 
Mean post-voiding 
residual urine 
volume (mL) 
(lower is better) 
Baseline: 126.9 vs. 115.4, P > 0.005 
1 month: 88.6 vs. 47.5, P = 0.0018 
3 months: 56.8 vs. 33.2, P = 0.012 
6 months: 39.2 vs. 30.9, P > 0.05 
12 months: 27.3 vs. 22.3, P > 0.05 
24 months: 19.4 vs. 15.2, P > 0.05 
Baseline: 127.0 ± 99.9 (20-230) vs.  
78.3 ± 73.3 (0-200), P > 0.05 
12 months: 62.3 ± 71.0 (0-250) vs.  
8.3 ± 11.9 (0-30), P = 0.006 
Safety 
Overall 
complications, n (%) 
30 (52.6) vs. 17 (29.8), P = 0.03 NR 
Perioperative 
complications, n (%) 
Intraoperative: 
Technical failure: 3 (5.3) vs 0 (0), P = 0.3 
Blood transfusion: 0 (0) vs 2 (3.8), P = 0.4 
Transurethral resection syndrome: 0 (0) vs  
1 (1.9), P = 0.97 
Early complications (<30 days): 
Postembolisation syndrome: 6 (11.1) vs 0 (0), 
P = 0.038 
Severe pelvic pain: 1 (1.9) vs 0 (0), P>0.99 
Acute urinary retention: 14 (25.9) vs 3 (5.7), 
P = 0.004 
Hematuria: 0 (0) vs 4 (7.5), P = 0.12 
Urinary tract infection: 1 (1.9) vs 2 (3.8),  
P = 0.99 
Clot retention: 0 (0) vs 1 (1.9), P = 0.99 
Late complications (30 days to 24 months): 
Clinical failure: 5 (9.4) vs 2 (3.9), P = 0.26 
Urethral stricture: 0 (0) vs 1 (2.1), P>0.99 
Bladder neck stenosis: 0 (0) vs 1 (2.1),  
P > 0.99 
Perioperative complications (PAE): 
Local pain at the prostate site, mild to 
moderate urethral burning during voiding 
and urinary frequency for 3-4 days  
post-procedure: 15 (100) 
Transient rectal bleeding: 1 (6.7) 
Hematospermia: 1 (6.7) 
Reduced ejaculate volume: 2 (13.3) 
Transient pubic bone ischaemia: 1 (6.7) 
Hematuria: 2 (13.3) 
Perioperative complications (TURP): 
Pollakuria, dysuria, hematuria for  
up to 2 weeks: 15 (100) 
Urinary incontinence: 4 (26.7) 
Intra-operative damage to left venous sinus 
and rupture of prostatic capsule: 1 (6.7) 
Hematuria requiring hospital readmission:  
1 (6.7) 
Retrograde ejaculation: 15 (100) 
Major adverse 
events, n (%)  
8 (14) vs. 4 (7), P = 0.3 0 (0) vs. 2 (13.3), P = NR 
Minor adverse 
events, n (%) 
22 (38.6) vs. 13 (22.8), P = 0.1 See above 
Radiation dose 
(dGy/cm2) 
1130.5 ± 267.1 vs. 0 ± 0, P < 0.0001 NR 
Procedure-related 
mortality, n (%)  
0 (0) 0 (0) 
Abbreviations: BPH = benign prostatic hyperplasia; dGy = decigray; cm = centimetre; IIEF = International Index of Erectile 
Function; IPSS = International Prostate Symptom Score; LUTS = lower urinary tract symptoms; mL = mililetre;  
ng = nanogram; NR = not reported; PAE = prostate artery embolisation; PSA = prostate specific antigen;  
PVA = polyvinyl alcohol; Qmax = Peak urinary flow; QoL = quality of life; TURP = transurethral prostate resection 
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Table A-2: Prostate artery embolisation: Results from observational studies; PAE vs open prostatectomy 
Author, year Russo, 2015 [4] 
Country Italy (OP)/Russia (PAE) 
Sponsor Not stated 
Intervention Bilateral PAE with tris-acryl microspheres (Embosphere; Merit Medical, USA) 
Comparator Open prostatectomy 
Study design Prospective 1:1 propensity score matched-pair comparison of  
patients treated at two centres 
Number of pts 80 (PAE) vs 80 (OP) 
Population Patients with moderate-severe LUTS due to BPH 
Inclusion criteria Symptomatic LUTS; IPSS ≥ 12; PSA level < 4 or PSA level 4 to 10 ng/mL – 
negative on biopsy; prostate volume > 80 cm3; Qmax < 15 mL/s 
Exclusion criteria Neurogenic bladder dysfunction; sphincter decompensation; coagulation 
disorders and/or anticoagulant therapy; chronic kidney disease; previous surgical 
or medical treatment for LUTS; life expectancy < 2 years; bladder stones; 
catheter or acute retention episode in last 4 weeks 
Age of patients (yrs)  67.0 ± 5.72 vs 68.38 ± 6.13, P = 0.19 
Follow-up 1, 6 and 12 months (all patients not lost to follow-up) 
Loss to follow-up, n (%) From 287 eligible patients, 18 (6.27) were lost to follow-up,  
82 (28.57) excluded by the matched-pair comparison 
Outcomes 
Efficacy 
Mean QoL score 
(lower is better) 
NR 
Mean IPSS 
(lower is better) 
Baseline: 23.98 ± 5.93 vs. 23.35 ± 4.66, P = 0.53 
1 month: 12.2 ± 3.95 vs. 6.02 ± 3.96, P < 0.01 
6 months: 11.35 ± 3.09 vs. 4.93 ± 3.33, P < 0.01 
12 months: 10.4 ± 4.66 vs. 4.31 ± 3.02, P < 0.01 
Mean IIEF score 
(higher is better) 
Baseline: 14.45 ± 4.83 vs. 15.10 ± 6.12, P = 0.56 
1 month: 15.25 ± 5.14 vs. 9.6 ±7.48, P < 0.01 
6 months: 15.53 ± 5.13 vs. 10.69 ± 7.76, P < 0.01 
12 months: 15.13 ± 5.07 vs. 10.88 ± 7.63, P < 0.01 
Symptom recurrence requiring 
re-intervention 
No paitents in either group required re-intervention 
Mean Qmax (mL/s) 
(higher is better) 
Baseline: 7.26 ± 3.29 vs. 7.85 ± 1.76, P = 0.21 
1 month: 14.95 ± 4.42 vs. 22.87 ± 5.03, P < 0.01 
6 months: 16.23 ± 4.49 vs. 24.5 ± 5.34, P < 0.01 
12 months: 16.89 ± 4.88 vs. 23.82 ± 5.92, P < 0.01 
Mean post-void residual (cm3) 
(lower is better) 
Baseline: 64.25 ± 33.10 vs. 64.95 ± 63.46, P = 0.95 
1 month: 19.75 ± 8.55 vs. 13.78 ± 10.2, P < 0.01 
6 months: 19.23 ± 10.13 vs. 4.31 ± 3.97, P < 0.01 
12 months: 18.38 ± 9.6 vs. 6.15 ± 4.26, P < 0.01 
Safety 
Overall complications, n (%) 7 (8.75) vs. 25 (31.25), P = NR 
Perioperative complications, n Grade 1: Hematuria: 0 vs 4; Urgency: 0 vs. 2; Hematospermia: 1 vs 0; Other: 5 vs 5 
Grade 2: UTI: 1 vs 3; Anemia: 0 vs. 5; Other: 0 vs 2 
Grade 3: Urethral/bladder neck stricture: 0 vs. 2; Urgency: 0 vs 1 
Major adverse events, n (%)  0 (0) vs. 3 (3.75), P = NR 
Minor adverse events, n (%) 7 (8.75) vs. 21 (26.25), P < 0.05 
Radiation dose (dGy/cm2) NR 
Procedure-related mortality, n (%)  0 (0) 
Abbreviations: BPH = benign prostatic hyperplasia; dGy = decigray; cm = centimetre; IIEF = International Index of Erectile 
Function; IPSS = International Prostate Symptom Score; LUTS = lower urinary tract symptoms; mL = mililetre;  
ng = nanogram; PAE = prostate artery embolisation; PSA = prostate specific antigen; PVA = polyvinyl alcohol;  
Qmax = Peak urinary flow; QoL = quality of life; TURP = transurethral prostate resection; UTI = urinary tract infection. 
Prostate artery embolisation for benign prostatic hyperplasia 
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Table A-3: Prostate artery embolisation: Results from a randomised controlled trial comparing PAE particle sizes 
Author, year Bilhim, 2013 [17] 
Country Portugal 
Sponsor Not stated, two authors were paid consultants to Cook Medical 
Intervention PAE with 80-180µm (mean 100µm) nonspherical PVA particles  
(Product NR; Cook Medical, USA) 
Comparator PAE with 180-300µm (mean 200µm) nonspherical PVA particles 
Study design Prospective randomised controlled trial 
Number of patients 40 (100µm PAE) vs. 40 (200µm PAE) 
Population Patients with moderate-severe LUTS secondary to BPH 
Inclusion criteria Age ≥ 40 years; symptomatic BPH refractory to medical therapy for  
≥ 6 months or experiencing acute urinary retention; prostate volume ≥ 30cm3; 
IPSS > 18 points and/or QoL score related to LUTS > 3 points 
Exclusion criteria Age <40 years; prostate or bladder malignancy; prostate volume <30cm2;  
IPSS ≤ 18 points, QoL ≤ 3 points; bladder diverticula >5cm or stones >2cm; 
chronic renal failure; acute urinary tract infection;  
atherosclerotic changes on CT angiography 
Age of patients (yrs)  Mean 64.4 ± 6.9 [100µm] vs Mean 63.4 ± 6.8 [200µm], P = 0.48 
Follow-up 1 week, 3 months and 6 months 
Mean follow-up NR 
Loss to follow-up, n (%) At 6 months (100µm vs. 200µm) 
6 (15.0) vs. 12 (30.0) 
Safety 
Overall complications, n (%) NR 
Perioperative complications, n (%) Pain (100µm vs. 200µm) 
During PAE: 3.20 ± 2.97 vs. 2.93 ± 3.28, P = 0.70 
6-8 hours after PAE: 0.10 ± 0.50 vs. 0, P = 0.20 
Week after PAE: 0.85 ± 1.65 vs. 0.87 ± 1.35, P = 0.96 
Adverse events 1-week post-PAE (100µm vs. 200µm) 
Dysuria/urethral bleeding: 8 (20) vs. 9 (22.5), P > 0.99 
Irritative voiding: 12 (30) vs. 16 (40), P = 0.48 
Hematospermia: 3 (7.5) vs. 2 (5), P > 0.99 
Hematuria: 3 (7.5) v.s 1 (2.5), P = 0.62 
Rectal bleeidng: 0 (0) vs. 1 (2.5), P > 0.99 
Urinary tract infection: 1 (2.5) vs. 1 (2.5), P > 0.99 
Inguinal hematoma: 2 (5) vs. 1 (2.5), P > 0.99 
Major adverse events, n (%)  0 (0) vs. 0 (0) 
Minor adverse events, n (%) See above (perioperative complications) 
Radiation dose (dGy/cm2) NR 
Procedure-related mortality, n (%)  0 (0) 
Abbreviations: BPH = benign prostatic hyperplasia; dGy = decigray; cm = centimetre; cm = centimetre;  
IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score; LUTS = lower urinary 
tract symptoms; mL = mililetre; ng = nanogram; PAE = prostate artery embolisation; PSA = prostate specific antigen;  
PVA = polyvinyl alcohol; Qmax = Peak urinary flow; QoL = quality of life;TURP = transurethral prostate resection. 
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Table A-4: Prostate artery embolisation: Results from observational studies of PAE; different populations, different particle sizes, single-arm trials 
Author, year Wang, 2016 [22] Wang, 2016 [21] Pisco, 2016 [20] Bilhim, 2016 [18] 
Country China China Portugal Portugal 
Sponsor National Scientific Foundation 
Committee of China and the Chinese 
PLA Scientific Foundation of the 
Twelve-five programme 
National Scientific Foundation 
Committee of China and the Chinese 
PLA Scientific Foundation of the 
Twelve-five programme 
NR NR 
Intervention Bilateral PAE with nsPVA  
(Product NR; Cook) in  
patients ≥ 75 years 
Unilateral or bilateral PAE with  
nsPVA (Product NR;  
Cook) in patients with medium  
(50-80 mL) prostate volume 
Unilateral or bilateral PAE with  
nsPVA (Product NR; Cook) in 418 pts; 
spherical PVA (Bead Block; 
Biocompatibles) in 167 pts; and  
in polyezene microspheres in  
33 (Embozene; Boston Scientific) pts. 
Unilateral or bilateral PAE with 
spherical PVA (Bead Block; 
Biocompatibles) 
Comparator Bilateral PAE with nsPVA (Product 
NR; Cook) in patients < 75 years 
PAE with nsPVA (Product not stated; 
Cook) in patients with large  
(> 80 mL) prostate volume 
Not applicable Not applicable 
Study design Prospective cohort study Prospective cohort study Retrospective case series Retrospective case series 
Number of pts 52 (≥ 75 years) 
105 (< 75 years) 
64 (volume > 80 mL) 
51 (volume 50-80 mL) 
630 186 
Population Patients with moderate-severe LUTS 
due to BPH that were refractor  
to medical treatment 
Patients with moderate-severe LUTS 
attributale to BPH and refractory  
to medical treatment. 
Patients with moderate-severe LUTS 
secondary to BPH 
Patients with moderate-severe LUTS 
secondary to BPH 
Inclusion criteria Age > 50 years; IPSS ≥ 18 and Qol ≥ 3; 
Qmax ≤ 12 mL/s or acute urinary 
retention; BPH refractory to medical 
treatments for at least 6 months; 
prostate volume > 40 mL on 
magnetic resonance imaging;  
Age > 50 years; IPSS ≥ 18 and QoL 
score > 3; Qmax < 12 mL; refreactory 
to medical treatments for at least  
6 months; prostate volume > 50 mL 
on magnetic resonance imaging 
Age > 40 years; BPH with IPSS ≥ 18 
and QoL ≥ 3; Qmax ≤ 12 mL/s or acute 
urinary retention; refractory to 
medical treatment for at least  
6 months; prostate volume < 30 ml  
if there was infravesical obstruction 
Age > 55 years; severe LUTS  
(IPSS ≥ 18); refractory to, or refusing, 
medical therapy; QoL score ≥ 3;  
Qmax of up to 12 mL/sec or acute 
urinary retention; prostate volume  
> 30 mL; sexual dysfunction or those 
willing to undergo tratement that 
might cause sexual dysfunction 
Exclusion criteria Pelvic malignancy; large bladder 
diverticula; large bladder stones; 
chronic renal failue; active UTI; 
neurogenic bladder and detrusor 
failure; urethral stricture;  
unregulated coagulation parameters; 
allergy to IV contrast 
Pelvic malignancy; large bladder 
diverticula; large bladder stones; 
chronic renal failue; active UTI; 
neurogenic bladder and detrusor 
failure; urethral stricture;  
unregulated coagulation parameters 
Malignancy, advanced atherosclerosis 
and tortuosity of arteries; secondary 
renal insufficiency; large bladder 
diverticula or stones; neurogenic 
bladder or detrusor failure; active UTI; 
unregulated and uncontrollable 
coagulation parameters 
Malignancy; advanced atherosclerosis 
and tortuosity of prostate and/or iliac 
arteries; secondary renal insufficiency; 
bladder stones or large diverticula; 
neurogenic bladder; detrusor muscle 
failure; active UTI; unregulated 
coagulation parameters 
Age of patients (yrs)  82.5 ± 7.5 (≥75 years) 
67.5 ± 14.0 (< 75 years) 
72.5 ± 9.5 (prostate volume> 80 mL) 
66.0 ± 8.5 (prostate volume 50-80 mL) 
65.1 ± 8.0 years 65.5 ± 7.79 years (sPVA arm) 
Follow-up (months) 1, 3 and 6 months,  
then every 6 months 
Mean 20 months (12-46) 
1, 3 and 6 months,  
then every 6 months 
Mean 17 months (12-33) 
1, 3 and 6 months, then every  
6 months for up to 3 years 
Median 24 months (12-78) 
1, 6, 12, 18 and 24 months 
Median 6 months (range NR) 
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Author, year Wang, 2016 [22] Wang, 2016 [21] Pisco, 2016 [20] Bilhim, 2016 [18] 
Loss to follow-up,  
n (%) 
10 (6.4) 12 months 
5 (9.8) (prostate volume > 80 mL) 
3 (4.7) (prostate volume 50-80 mL) 
47 (7.5) 6 months: 68 (36.6)  
12 months: 147 (79.0) 
Outcomes 
Safety 
Overall 
complications, n (%) 
NR NR NR NR 
Major adverse 
events, n (%)  
0 (0) 0 (0) Bladder wall ischemia: 1 (0.2) 
Persistent perineal pain: 1 (0.2) 
0 (0) 
Minor adverse 
events, n (%) 
Age ≥75 vs. <75 years 
Urethral burning: 10 (19.2) vs  
12 (11.4), P = 0.027 
Haematuria: 6 (11.5) vs 8 (7.6),  
P = 0.722 
Haematospermia: 4 (7.7) vs 8 (7.6),  
P = 0.656 
Rectal bleeding: 4 (7.7) vs 7 (6.7),  
P = 0.604 
Acute urinary retention: 16 (30.8) vs  
9 (8.6), P = 0.031 
Inguinal hematoma: 3 (5.8) vs 3 (2.9), 
P = 0.060 
Prostate volume > 80 mL vs. 50-80 mL 
Urethral burning: 10 (16.7) vs 5 (10.2), 
P = 0.04 
Haematuria: 7 (11.7) vs 4 (8.2),  
P = 0.8 
Haematospermia: 7 (11.2) vs 4 (8.2),  
P = 0.8 
Rectal bleeding: 6 (10.0) vs 4 (8.2),  
P = 0.7 
Acute urinary retention:  
17 (28.3) vs 5 (10.2), P = 0.02 
Dysuria: 152 (24.1) 
Frequency: 145 (23.0) 
Obstipation: 76 (13.3) 
Hematuria: 48 (8.0) 
Hematospermia: 46 (8.0) 
Rectal bleeding: 34 (5.9) 
Urinary tract infection: 27 (4.7) 
Acute urinary retention: 11 (1.9) 
Inguinal hematoma: 12 (1.9) 
Balanitis: 4 (0.7) 
Urinary frequency of greater severity 
than baseline 95 (51.1) 
Dysuria 79 (42.5) 
Hematospermia 15 (8.1) 
Hematuria 14 (7.5) 
Rectal bleeding 10 (5.4) 
Groin hematoma 6 (3.2) 
UTI 1 (4.8) 
Skin lesions 9 (4.8) 
Transient decrease in  
erectile function 6 (3.2) 
Radiation dose 
(dGy/cm2) 
NR NR NR Median 2401 (range: 655-9202) 
Procedure-related 
mortality, n (%)  
0 (0) 0 (0) 0 (0) 0 (0) 
Abbreviations: BPH = benign prostatic hyperplasia; dGy = decigray; cm = centimetre; IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score;  
LUTS = lower urinary tract symptoms; mL = mililetre; ng = nanogram; ns = non spherical; PAE = prostate artery embolisation; PSA = prostate specific antigen; PVA = polyvinyl alcohol; 
Qmax = Peak urinary flow; QoL = quality of life; s = spherical; TURP = transurethral prostate resection; UTI = urinary tract infection. 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[12] and in the Guidelines of EUnetHTA [11].  
Table A-5: Risk of bias – existing systematic reviews of PAE for BPH [10] 
AMSTAR Item 
Wang et al  
2016 [54] 
Feng et al  
2016 [55] 
Schreuder et al 
2014 [56] 
Shim et al  
2016 [57] 
Teoh et al  
2016 [58] 
Uflacker et al 
2016 [59] 
11. Was an ‘a priori’ design provided? No No Yes Yes No Yes 
12. Was there duplicate study selection and data extraction? Yes Yes Yes No/Can’t answer No/Can’t answer Yes 
13. Was a comprehensive literature search performed? Yes Yes No/Can’t answer No/Can’t answer Yes No/Can’t answer 
14. Was the status of publication (i.e. grey literature) used  
as an inclusion criterion? 
Can’t answer No No No No/Can’t answer No 
15. Was a list of studies (included and excluded) provided? No No No No No No 
16. Were the characteristics of the included studies provided? Yes Yes Yes Yes Yes Yes 
17. Was the scientific quality of the included studies assessed  
and documented? 
Yes No Yes Yes Yes Yes 
18. Was the scientific quality of the included studies used 
appropriately in formulating conclusions?  
No No Yes No Yes Yes 
19. Were the methods used to combine the findings of studies 
appropriate? 
Yes Yes Not applicable No Not applicable Yes 
10. Was the likelihood of publication bias assessed? No No No No No No 
11. Was the conflict of interest included? No No Yes No No Yes 
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Table A-6: Risk of bias – study level (randomised studies) see [60] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely* 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
PAE vs TURP 
Gao et al, 2014 [19] Yes NoA No No Yes NoB HighA,B 
Carnevale, 2016 [3] UnclearC UnclearD Unclear Unclear Unclear Noe HighC,D,E 
100µm PAE vs 200µm PAE 
Bilhim, 2013 [17] Yes UnclearD Yes No Unclear NoF,G HighD,F,G 
* This risk was defined as unclear if author’s didn’t explicitly state that a protocol was published before/the study was not registered; 
A Patients were aware of their allocation prior to the procedure (and hence so to were investigators), and were given the option to change allocation.  
Only patients that agreed to their allocation were included in the analysis 
B Some patients had repeat procedures during the study period 
C Randomisation method was not reported 
D It was not reported if operators were blinded to the allocation sequence prior to inclusion 
E Patients in the TURP and PAE groups had significantly different Qmax and bladder contractility index scores at baseline (and likely prostate volume,  
but differences were not reported adequately) 
F Not all patients were included in the efficacy analysis 
G Patients had additional treatments after PAE, but it was unclear if this was during the study period or after last follow-up 
Table A-7: Risk of bias – study level (non–randomised studies) see [61] 
Study  
reference/ID 
Bias due to 
confounding 
Bias selection of 
participants into 
the study 
Bias in 
measurement of 
interventions 
Bias due to departures 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement of 
outcomes 
Bias in selection  
of the reported 
results Overall Bias 
PAE vs open prostatectomy 
Russo, 2015 [4] Moderate Low Low Low Moderate ModerateA Moderate Moderate 
PAE (small vs. medium vs. large prostate size) 
Wang, 2016 [21] SeriousB Low Low Moderate Moderate ModerateC Moderate SeriousD 
PAE (age <75 vs. > 75 years) 
Wang, 2016 [22] SeriousE Moderate Low Moderate Moderate ModerateF Moderate SeriousG 
A Investigators and patients were aware of the assigned intervention. 
B Significant differences in patient demographics (age, IIEF-5 score, prostate volume) were not controlled for in the analysis. 
C Investigators and patients were aware of the assigned intervention. 
D One or more criteria scored as “serious”, but none as critical. 
E Groups were significantly different at baseline (heart disease, hypertension, COPD, urinary retention, antiplatelet use, Qmax, post-void residual volume,  
PSA, IIEF score), but this was largely by design (older versus younger patients). Most important confounding factors were measured. 
F Investigators and patients were aware of the assigned intervention. 
G One or more criteria scored as “serious”, but none as critical. 
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Table A-8: Risk of bias – study level (case series), see [13] 
Study reference/ID 
Pisco,  
2016 [20] 
Bilhim,  
2016 [62] 
Study objective 
11. Is the hypothesis/aim/objective of the study stated clearly in the abstract, 
introduction, or methods section? 
Yes Yes 
Study population 
12. Are the characteristics of the participants included in the study described? Yes Yes 
13. Were the cases collected in more than one centre? No No 
14. Are the eligibility criteria (inclusion and exclusion criteria) for entry into  
the study explicit and appropriate? 
Yes Yes 
15. Were participants recruited consecutively? Yes Unclear 
16. Did participants enter the study at similar point in the disease? Yes Yes 
Intervention and co-intervention 
17. Was the intervention clearly described in the study? Yes Yes 
18. Were additional interventions (co-interventions) clearly reported in the study? Yes Yes 
Outcome measures 
19. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes 
10. Were relevant outcomes appropriately measured with objective and/or  
subjective methods? 
Yes Yes 
11. Were outcomes measured before and after intervention? Yes Yes 
Statistical Analysis 
12. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes 
14. Was the loss to follow-up reported? N/AA Unclear 
15. Does the study provide estimates of the random variability in the data analysis  
of relevant outcomes? 
Yes Yes 
16. Are adverse events reported? Yes Yes 
17. Are the conclusions of the study supported by results? Yes Yes 
Competing interest and source of support 
18. Are both competing interest and source of support for the study reported? Yes Yes 
Overall Risk of bias Low Low 
A Study was a retrospective cohort study, losses to follow-up were not relevant, only patients with complete data were included. 
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Applicability table 
Table A-9: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Most studies only included patients with severe LUTS (i.e. IPSS > 18), which is likely to have 
influenced the treatment effects relative to the target population (i.e. IPSS > 8). The remaining 
study populations did not differ in any significant way from the population intended for clinical 
practice. The mean age of participants was consistent across studies (median 65.75 years,  
range 62.7-72.5), and was reflective of the target population in clinical practice. 
Intervention The interventions ranged between particle size and shape. Particle size varied between a mean 
100µm to 200µm in diameter. Particles were either spherical or non-spherical. Some procedures 
were bilateral, while others were unilateral. Most particles were made of PVA. Three studies did not 
report what material of particles were made from. It is unclear if variations in the type of embolisation 
agent are likely to have a meaningful impact on patient outcomes. 
Comparators The comparators in the RCTs (i.e. TURP), and the matched pairs comparison (i.e. open prostatectomy) 
represent the current standard of care for moderate-to-severe LUTS secondary to BPH. 
Outcomes Not all critical efficacy outcomes were reported by all studies. Gao et al (2014) did not report IIEF. 
Gao et al (2014) and Carnevale et al (2016) reported all outcomes at a minimum 12-month follow-up. 
Gao et al (2014) reported all outcomes at 24 months follow-up. Safety was reported variably, and was 
measured using different scales. As a result, we have a low level of confidence in the reported rates 
of minor adverse events, but a moderate degree of confidence that adverse events occur rarely in PAE. 
Setting The included randomised evidence of PAE compared to TURP was conducted in China and Brazil. 
The matched pairs trial of PAE compared to open prostatectomy was conducted in Italy and Russia.  
Single arm evidence for the safety of PAE was conducted in China, Portugal, and the United States 
of America. 
All studies were conducted in tertiary teaching hospitals. PAE was conducted exclusively in 
interventional radiology departments, while comparators were conducted in Urology departments. 
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List of ongoing clinical trials 
Table A-10: List of ongoing randomised controlled trials of PAE compared to TURP 
Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT02054013 
Prostatic Artery Embolisation vs. 
Conventional Transurethral 
Prostatectomy in the Treatment  
of Benign Prostatic Hyperplasia 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first line 
medical therapy 
100 PAE TURP Changes in IPSS (time 
frame: 12 weeks, 24 
months) 
February 
2021 
Daniel Stephan 
Engeler, MD, 
Cantonal Hospital  
St Gallen 
NCT01789840 
Prostate Artery Embolisation With 
Embosphere Microspheres Compared to 
TURP for Benign Prostatic Hyperplasia 
Moderate-to-severe 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
186 PAE with 
Embosphere® 
Microspheres 
(Merit Medical, 
USA) 
TURP Change in IPSS (time 
frame:12 months) 
May 2018 Merit Medical 
Systems, Inc. 
NCT02566551 
Prospective Controlled Randomized 
Study of PAE vs TURP for BPH 
Treatment 
Moderate-to-severe 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
100 PAE with gelatin 
microspheres 
TURP Change in IPSS (time 
frame:12 months) 
April 2018 Group of Research  
in Minimally Invasive 
Techniques 
NCT01963312 
Clinical Trial to Evaluate the Efficacy 
and Safety of the Transarterial Supra-
selective Embolisation of the Prostate 
to Treat the Urinary Symptoms 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first-line 
medical therapy 
60 PAE with  
Bead Block 
(Biocompatibles 
UK Ltd) 
TURP Change in maximum 
urinary flow (time 
frame: 12 months) 
December 
2016 
Fundacion  
Miguel Servet 
DRKS00008079 
Prospective randomised interventional 
single-center study to evaluate pre-
operative transarterial embolisation of 
the prostate before prostatectomy 
Moderate-to-severe 
LUTS secondary to 
BPH 
100 PAE prior to  
TURP 
TURP without  
prior PAE 
Conversion of patients 
primarily planned for 
open prostatectomy to 
TURP or conservative 
management (time 
frame: not stated) 
Not 
reported 
Universität des 
Saarlandes 
 
Table A-11: List of ongoing randomised controlled trials of PAE compared to medical therapy 
Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT02869971 
Prostatic Artery Embolisation Versus 
Medical Treatment in Symptomatic 
Benign Prostatic Hyperplasia (PARTEM) 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first line 
medical therapy 
90 PAE with 
Embosphere® 
Microspheres  
(Merit Medical, USA) 
Drug therapy with 
Combodart® 
(GlaxoSmithKline, 
UK) 
Change in IPSS score 
(time frame:  
3, 9, 18, 24 months) 
February 
2021 
Assistance Publique - 
Hopitaux de Paris 
Ministry of Health, 
France 
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Table A-12: List of ongoing randomised controlled trials of PAE compared to sham procedure 
Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT02074644 
Clinical Trial of Prostatic Arterial 
Embolisation Versus a Sham Procedure 
to Treat Benign Prostatic Hyperplasia 
Moderate-to-severe 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
80 PAE with  
Bead Block 
(Biocompatibles 
UK Ltd) 
Sham procedure 
(catheterisation 
with angiography 
but no 
embolisation) 
Change in IPSS (time 
frame: 6 months) 
September 
2017 
João Martins Pisco, 
MD PhD, Hospital  
St. Louis 
 
Table A-13: List of ongoing observational trials of PAE 
Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT01924988 
Prostate Embolisation for  
Benign Prostatic Hyperplasia 
LUTS secondary  
to BPH 
30 PAE with 
Embosphere® 
Microspheres  
(Merit Medical, USA) 
None Bladder or rectal 
ischemic injury (time 
frame: 1 week,  
3, 6 and 12 months) 
January 
2019 
James B. Spies, MD, 
Georgetown 
University  
Medical Center 
NCT02849522 
ROPE Registry Project to Determine 
the Safety and Efficacy of Prostate 
Artery Embolisation for Lower Urinary 
Tract Symptoms Secondary to Benign 
Prostatic Enlargement 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first-line 
medical therapy 
300 PAE TURP or open 
prostatectomy 
Change in IPSS (time 
frame: 12 months) 
September 
2017 
Cedar, United 
Kingdom 
National Institute for 
Health and Care 
Excellence (NICE) 
British Society of 
Interventional 
Radiologists (BSIR) 
British Association of 
Urological Surgeons 
(BAUS) 
NCT02434575 
ROPE Registry Project to Determine 
the Safety and Efficacy of Prostate 
Artery Embolisation for Lower Urinary 
Tract Symptoms Secondary to Benign 
Prostatic Enlargement 
LUTS secondary  
to BPH 
300 PAE TURP or open 
prostectomy 
Change in IPSS  
(time frame:  
12 months) 
December 
2016 
Cardiff and Vale 
University Health 
Board 
British Society of 
Interventional 
Radiologists 
British Association of 
Urological Surgeons 
National Instutite of 
Health and Care 
Excellence 
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Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT02509975 
Safety and Efficacy of OCL 503 in 
Prostate Artery Embolisation 
Moderate-to-severe 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
15 PAE with OCL 503 
(IMBiotechnologie
s Ltd., Canada) 
None Adverse events (time 
frame: 12 months) 
Change in IPSS  
(time frame:  
12 months) 
March 2017 IMBiotechnologies 
Ltd. 
NCT02822924 
Prostate Artery Embolisation for 
Symptomatic Benign Prostatic 
Hyperplasia 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
40 PAE None Successful prostatic 
arterial catheterisation 
and embolisation  
(time frame:  
1 hour post-procedure) 
April 2018 Chinese University  
of Hong Kong 
NCT02026908 
Prostatic Artery Embolisation for 
Treatment of Benign Prostatic 
Hyperplasia 
LUTS secondary to 
BPH, failed or refused 
first-line medical 
therapy 
50 PAE None Adverse events  
(time frame: 5 years) 
January 
2020 
Northwestern 
University 
NCT02167919 
Efficacy of Prostatic Artery Embolisation 
in Patients With Severe Benign 
Prostatic Hyperplasia 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first line 
medical therapy 
15 PAE None Redction in prostate 
size (time frame: 1 year) 
Improvement of LUTS 
(time frame: 1 year) 
May 2017 University of  
North Carolina 
NCT02930889 
Prostate Artery Embolisation for Lower 
Urinary Tract Symptoms Due to Benign 
Prostatic Hyperplasia 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first line 
medical therapy 
100 PAE None Adverse events  
(time frame: 3 months) 
October 
2021 
University of 
Minnesota 
NCT02206243 
Embozene® Microspheres for Prostatic 
Arterial Embolisation in Patients With 
Symptomatic Benign Prostatic 
Hyperplasia (EmboProstate) 
Severe LUTS 
secondary to BPH, 
failed or refused first 
line medical therapy 
7 PAE with 
Embosphere® 
Microspheres  
(Merit Medical, 
USA) 
None Change in IPSS and 
peak flow rate  
(time frame:  
3 and 6 months) 
December 
2016 
Jena University 
Hospital 
Boston Scientific 
Corporation 
NCT02679430 
Analysis of Prostatic Arterial 
Embolisation for Benign Prostatic 
Hyperplasia Using Embosphere 
Microspheres 
Moderate-to-severe 
LUTS secondary to 
BPH, failed first line 
medical therapy 
16 PAE with 
Embosphere® 
Microspheres  
(Merit Medical, 
USA) 
None Change in IPSS  
(time frame:  
12 months)  
November 
2017 
Sergei Sobolevsky, 
MD, Maimonides 
Medical Center 
NCT02396420 
Prostate Artery Embolisation as  
a Treatment for Benign Prostatic 
Hyperplasia in Men With Prostates 
Larger Than 90 Grams 
Moderate-to-severe 
LUTS secondary  
to BPH, failed or 
refused first-line 
medical therapy 
60 PAE with 
Embosphere® 
Microspheres  
(Merit Medical, 
USA) 
None Change in IPSS  
(time frame:  
12 months) 
November 
2022 
South Florida 
Medical Imaging, PA 
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Identifier/Trial name Patient population 
Estimated 
enrolment Intervention Comparison Primary Outcome 
Estimated 
completion Sponsors 
NCT02676544 
Prostate Embolisation for Massive 
Benign Prostatic Hypertrophy 
Moderate-to-severe 
LUTS secondary  
to BPH 
50 PAE with 
Embosphere® 
Microspheres 
(Merit Medical, 
USA) 
None Change in IPSS  
(time frame:  
24 months) 
July 2017 Rhode Island 
Hospital 
NCT02167009 
Benign Prostatic Hyperplasia and 
Prostate Size Greater Than 90 Grams 
Moderate-to-severe 
LUTS secondary  
to BPH, failed or 
refused first-line 
medical therapy 
30 PAE with 
Embosphere® 
Microspheres 
(Merit Medical, 
USA) 
None Change in IPSS  
(time frame: 
12 months) 
May 2019 Tampa General 
Hospital 
NCT02689830 
Prostate Embolisation for Acute 
Urinary Retention Study 
Acute urinary 
retention secondary 
to BPH. 
20 PAE with  
Bead Block 
(Biocompatibles 
UK Ltd) 
None Procedure success, 
indicated by lack of 
surgery or cateheter 
post-procedure  
(time frame: 6 months) 
December 
2017 
ClinSearch 
Biocompatibles UK 
Ltd 
European Georges 
Pompidou Hospital 
NCT02592473 
Prostate Artery Embolisation for 
Treatment of Benign Prostatic 
Hyperplasia 
LUTS secondary  
to BPH 
50 PAE with 
Embozene 
Microspheres 
None Change in maximum 
urinary flow (time 
frame: 12, 24 months) 
Adverse events  
(time frame:  
12, 24 months) 
Change in IPSS  
(time frame:  
12, 24 months) 
Change in quality of life 
(time frame:  
12, 24 months) 
November 
2017 
University of Virginia 
Siemens Medical 
Solutions 
DRKS00006308 
Prospective, single-center, clinical trial 
phase - I- II study to evaluate the safety 
and clinical feasibility and efficacy of 
arterial Prostataembolisation in patients 
with moderate-to-severe symptomatic 
benign prostatic hyperplasia 
Moderate-to-severe 
LUTS secondary  
to BPH, failed or 
refused first-line 
medical therapy 
36 PAE None Post-operative 
complications  
(time frame:  
not stated) 
Not 
reported 
Universitätsklinikum 
Magdeburg 
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Literature search strategies 
Search strategy for the Cochrane Library 
Search Name: Prostate Artery Embolisation 
Database Cochrane library 
Search Date: 09/12/2016 
ID Search 
#1 MeSH descriptor: [Prostatic Hyperplasia] explode all trees 
#2 Prostat* near Hypertroph* (Word variations have been searched) 
#3 benign prostat* hyperplasia* (Word variations have been searched) 
#4 BPH:ti,ab,kw (Word variations have been searched) 
#5 #1 or #2 or #3 or #4 
#6 MeSH descriptor: [Embolisation, Therapeutic] explode all trees 
#7 prostat* artery embolisation* (Word variations have been searched) 
#8 prostat* artery embolisation* (Word variations have been searched) 
#9 MeSH descriptor: [Microspheres] explode all trees 
#10 Embosphere* (Word variations have been searched) 
#11 Embozene* (Word variations have been searched) 
#12 Bead Block* (Word variations have been searched) 
#13 Merit Medical (Word variations have been searched) 
#14 Boston Scientific (Word variations have been searched) 
#15 CeloNova (Word variations have been searched) 
#16 “Biocompatibles” (Word variations have been searched) 
#17 “PAE”:ti,ab,kw (Word variations have been searched) 
#18 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 
#19 #5 and #18 
Total: 26 Hits 
 
 
Search strategy for MEDLINE 
Search Name: Prostate Artery Embolisation 
Database: Ovid MEDLINE(R) Epub Ahead of Print <December 08, 2016>, Ovid MEDLINE(R) <1946 to November 
Week 5 2016>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 08, 2016>, Ovid 
MEDLINE(R) Daily Update <December 07, 2016> 
Search Date: 09/12/2016 
ID Search 
#1 exp Prostatic Hyperplasia/ 
#2 Prostat* Hypertroph*.mp.  
#3 benign prostatic hyperplasia*.mp.  
#4 BPH.mp. 
#5 1 or 2 or 3 or 4 
#6 exp Embolisation, Therapeutic/ 
#7 prostat* artery emboli#ation*.mp. 
#8 exp Microspheres/ 
#9 Embosphere*.mp. 
Prostate artery embolisation for benign prostatic hyperplasia 
66 LBI-HTA | 2017 
#10 Embozene*.mp. 
#11 Bead Block*.mp. 
#12 Merit Medical.mp.  
#13 Boston Scientific.mp. 
#14 CeloNova.mp.  
#15 Biocompatibles.mp.  
#16 PAE.mp. 
#17 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
#18 5 and 17 
Total: 190 Hits 
 
 
Search strategy for Embase 
Search Name: Prostate Artery Embolisation 
Search Date: 09/12/2016 
ID Search 
#1 ‘prostate hypertrophy’/exp 
#2 ‘benign prostat* hyperplasia*’ 
#3 bph:ti,ab 
#4 ‘prostate hypertrophy’/exp OR ‘benign prostat* hyperplasia*’ OR bph:ti,ab 
#5 ‘artificial embolism’/exp 
#6 ‘prostat* artery emboli*ation*’ 
#7 ‘microsphere’/exp 
#8 embosphere*:tn,dn  
#9 embozene*:tn,dn  
#10 ‘embolic particle’/exp 
#11 ‘bead block*’:tn,dn  
#12 ‘merit medical’:df,mn 
#13 ‘boston scientific’:df,mn 
#14 celonova:df,mn 
#15 biocompatibles:df,mn 
#16 pae:ab,ti 
#17 ‘artificial embolism’/exp OR ‘prostat* artery emboli*ation*’ OR ‘microsphere’/exp OR embosphere*:tn,dn 
OR embozene*:tn,dn OR ‘embolic particle’/exp OR ‘bead block*’:tn,dn OR ‘merit medical’:df,mn OR ‘boston 
scientific’:df,mn OR celonova:df,mn OR biocompatibles:df,mn OR pae:ab,ti 
#18 ‘prostate hypertrophy’/exp OR ‘benign prostat* hyperplasia*’ OR bph:ti,ab AND (‘artificial embolism’/exp 
OR ‘prostat* artery emboli*ation*’ OR ‘microsphere’/exp OR embosphere*:tn,dn OR embozene*:tn,dn OR 
‘embolic particle’/exp OR ‘bead block*’:tn,dn OR ‘merit medical’:df,mn OR ‘boston scientific’:df,mn OR 
celonova:df,mn OR biocompatibles:df,mn OR pae:ab,ti) 
Total: 319 Hits 
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Search strategy for CRD (DARE, NHS-EED, HTA) 
Search Name: Prostate Artery Embolisation 
Search Date: 09/12/2016 
ID Search 
#1 MeSH DESCRIPTOR Prostatic Hyperplasia EXPLODE ALL TREES 
#2 (Prostat* NEAR Hypertroph*) 
#3 (benign prostatic hyperplasia*) 
#4 (BPH) 
#5 #1 OR #2 OR #3 OR #4 
#6 MeSH DESCRIPTOR Embolisation, Therapeutic EXPLODE ALL TREES 
#7 (prostat* artery embolisation*) 
#8 (prostat* artery embolisation*) 
#9 MeSH DESCRIPTOR Microspheres EXPLODE ALL TREES 
#10 (Embosphere*) 
#11 (Embozene*) 
#12 (Bead Block*) 
#13 (Merit Medical) 
#14 (Boston Scientific) 
#15 (CeloNova) 
#16 (Biocompatibles) 
#17 (PAE) 
#18 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
#19 #5 AND #18 
Total: 1 Hit 
 
 
  
 
